0001628280-22-004376 | POS AM | XBRL Viewer

Print Document View Excel Document

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 46,637,000	$ 1,309,000
Restricted cash	490,000	565,000
Marketable securities	397,458,000	0
Other receivables	2,612,000	48,000
Derivative asset	202,000	0
Prepaid expenses and other current assets	3,774,000	83,000
Total current assets	451,173,000	2,005,000
Property, plant, and equipment, net	0	0
Operating lease right-of-use asset	1,782,000	0
Intangible assets, net	215,000	258,000
Other long-term assets	62,000	62,000
Total assets	510,417,000	47,429,000
Current liabilities
Accounts payable	2,451,000	2,700,000
Accrued expenses	973,000	593,000
Operating lease liability, current	280,000	0
Other liabilities, current	380,000	0
Derivative liability	103,000	1,239,000
Stockholder convertible notes payable	0	3,232,000
Total current liabilities	4,187,000	7,764,000
PPP Loan	0	906,000
Earnout liability	127,757,000	0
Canadian Government Research and Development Program Liability	6,762,000	6,197,000
Redeemable convertible preferred stock warrants	0	19,233,000
Assumed common stock warrants liability	52,860,000	0
Stockholder note	5,189,000	5,189,000
Related party other liabilities, long-term	5,720,000	5,517,000
Operating lease liability	1,486,000	0
Other liabilities, long-term	2,946,000	2,500,000
Total liabilities	206,907,000	47,306,000
Commitments and contingencies (See Note 19)
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and December 31, 2020	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 136,801,569 and 70,266,925, issued and outstanding as of December 31, 2021 and December 31, 2020, respectively	16,000	6,000
Additional paid-in capital	361,542,000	98,620,000
Accumulated deficit	(56,797,000)	(98,887,000)
Accumulated other comprehensive income (loss)	(1,251,000)	384,000
Total stockholders’ equity	303,510,000	123,000
Total liabilities and stockholders’ equity	$ 510,417,000	$ 47,429,000

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	141,301,569	70,266,925
Common stock, shares outstanding (in shares)	141,301,569	70,266,925
Sponsor vesting shares outstanding (in shares)	4,500,000
Sponsor vesting shares issued (in shares)	4,500,000

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating Expenses
Research and development	$ 9,124	$ 4,138
General and administrative	17,265	6,563
Depreciation and amortization	544	479
Total operating expenses and loss from operations	26,933	11,180
Other (income) expenses
Interest income	(1,413)	0
Interest expense, net of capitalized interest	2,838	341
Change in fair value of derivatives	1,326	1,088
Change in fair value of warrants liability	4,525	18,498
Change in fair value of earnout liability	(75,488)	0
Other income, net	(811)	(805)
Total other (income) expenses, net	(69,023)	19,122
Net income (loss)	42,090	(30,302)
Other comprehensive income (loss)
Unrealized (loss) on marketable securities	(1,712)	0
Foreign currency translation adjustment, net of tax	77	794
Total comprehensive income (loss)	$ 40,455	$ (29,508)
Net income (loss) per share, basic (in dollars per share)	$ 0.42	$ (0.48)
Net income (loss) per share, diluted (in dollars per share)	$ 0.40	$ (0.48)
Weighted-average common shares outstanding, basic (in shares)	101,221,781	62,544,933
Weighted-average common shares outstanding, diluted (in shares)	106,237,754	62,544,933

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity - USD ($) $ in Thousands	Total	Series A	Series B	Series C	Previously Reported	Previously Reported Series A	Previously Reported Series B	Previously Reported Series C	Revision of Prior Period, Adjustment	Revision of Prior Period, Adjustment Series A	Revision of Prior Period, Adjustment Series B	Revision of Prior Period, Adjustment Series C	Legacy Origin Common Stock	Legacy Origin Common Stock Previously Reported	Legacy Origin Common Stock Revision of Prior Period, Adjustment	Common Stock	Common Stock Previously Reported	Common Stock Revision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital Revision of Prior Period, Adjustment	Accumulated Deficit	Accumulated Deficit Previously Reported	Accumulated Other Comprehensive Income (loss)	Accumulated Other Comprehensive Income (loss) Previously Reported
Balance beginning (in shares) at Dec. 31, 2019													0	1,283,788	(1,283,788)	62,542,363	0	62,542,363
Balance beginning at Dec. 31, 2019	$ 27,999				$ (67,984)				$ 95,983				$ 0	$ 0		$ 6	$ 0	$ 6	$ 96,988	$ 1,011	$ 95,977	$ (68,585)	$ (68,585)	$ (410)	$ (410)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options (in shares)																2,912
Common stock issued upon exercise of stock options	2																		2
Stock-based compensation	1,630																		1,630
Net income	(30,302)																					(30,302)
Other comprehensive loss	794																							794
Ending balance at Dec. 31, 2020	123															$ 6			98,620			(98,887)		384
Ending balance (in shares) at Dec. 31, 2020																62,545,275
Beginning balance (in shares) at Dec. 31, 2019		0	0	0		13,204,284	6,275,704	1,590,675		(13,204,284)	(6,275,704)	(1,590,675)
Beginning balance at Dec. 31, 2019		$ 0	$ 0	$ 0		$ 31,478	$ 41,125	$ 23,380		$ (31,478)	$ (41,125)	$ (23,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Reclassification of stockholders' convertible notes payable (in shares)																2,049,191
Reclassification of stockholders’ convertible notes payable	20,491																		20,491
Reclassification of redeemable convertible preferred stock warrant liability (in shares)																5,554,440
Reclassification of redeemable convertible preferred stock warrant liability	54,274															$ 7			54,267
Business Combination, net of redemptions and equity issuance costs of $37 million (in shares)																70,981,545
Business Combination, net of redemptions and equity issuance costs of $37 million	385,405																		385,405
Reclassification of equity to liability related to earn out provisions of Business Combination (see note 13)	(203,082)																		(203,082)
Common stock issued upon exercise of stock options (in shares)																171,118
Common stock issued upon exercise of stock options	77															$ 3			74
Stock-based compensation	5,767																		5,767
Net income	42,090																					42,090
Other comprehensive loss	(1,635)																							(1,635)
Ending balance at Dec. 31, 2021	$ 303,510															$ 16			$ 361,542			$ (56,797)		$ (1,251)
Ending balance (in shares) at Dec. 31, 2021																141,301,569

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Equity issuance costs	$ 37

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income (loss)	$ 42,090	$ (30,302)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization	544	479
Amortization on right-of-use asset	280	0
Stock-based compensation	5,767	1,630
Amortization of debt issuance costs	14	90
Accretion of debt discount	2,211	101
Change in fair value of derivatives	1,326	1,088
Change in fair value of warrants liability	4,525	18,498
Change in fair value of earnout liability	(75,488)	0
Operating cash flows from operating leases	(295)	0
Changes in operating assets and liabilities:
Other receivables	(2,563)	1,007
Grants receivable	0	87
Prepaid expenses and other current assets	(3,652)	53
Increase in other liabilities, current	380	0
Accounts payable	(395)	1,203
Accrued expenses	3,010	349
Related party payable	203	256
Net cash used in operating activities	(22,043)	(5,461)
Cash flows from investing activities
Purchases of property, plant, and equipment, net of grants	(12,268)	(1,786)
Purchases of marketable securities	(2,448,316)	0
Sales of marketable securities	2,024,089	0
Maturities of marketable securities	25,058	0
Capitalized interest on plant construction	(201)	(268)
Net cash used in investing activities	(411,638)	(2,054)
Cash flows from financing activities
Proceeds from stockholders' notes payable, net of debt issuance costs	11,707	3,166
Payment of short-term debt	(906)	0
Proceeds from Canadian Government Research and Development Program	543	2,662
Issuance of common stock	74	1
Business combination, net of issuance costs paid	467,530	0
Net cash provided by financing activities	478,948	5,829
Effects of foreign exchange rate changes on the balance of cash and cash equivalents, and restricted cash held in foreign currencies	(14)	(52)
Net increase (decrease) in cash and cash equivalents, and restricted cash	45,253	(1,738)
Cash and cash equivalents, and restricted cash, beginning of the period	1,874	3,612
Cash and cash equivalents, and restricted cash, end of the period	47,127	1,874
Supplemental disclosure of cash flow information
Conversion of stockholder convertible notes payable to common stock	20,493	0
Reclassification of redeemable convertible preferred stock warrants to common stock	54,267	0
Reclassification of contingently issued equity to liability	203,082	0
Net assets assumed from business combination	81,364	0
Debt discount related to derivative liability	2,196	0
Business combination transaction costs, accrued but not paid	609	0
Operating lease right-of-use assets obtained in exchange for lease obligations	$ 2,062	$ 0

Organization and Business	12 Months Ended
Organization and Business	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business Unless the context otherwise requires, references in these notes to “Origin”, “the Company”, “we”, “us” and “our” and any related terms are intended to mean the post-Business Combination Origin Materials, Inc. and its consolidated subsidiaries. The Company’s mission to help enable the world’s transition to sustainable materials by replacing petroleum-based materials with decarbonized materials in a wide range of end products, such as food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments and more. The Company’s technology can convert sustainable feedstocks, such as sustainably harvested wood, agricultural waste, wood waste and corrugated cardboard, into materials and products that are currently made from fossil feedstocks, such as petroleum and natural gas. The Company’s products are intended to compete directly with petroleum-derived products on both performance and price, as well as provide a significant unit cost advantage over products made from other low-carbon feedstocks. The Company is currently developing and constructing its first manufacturing plant in Ontario, Canada (Origin 1), which is expected to become operational in 2022. The Company is also currently in the planning phase for the construction of a significantly larger manufacturing plant (Origin 2), with which is expected to become operational in 2025. On June 25, 2021 (the “Closing Date”), Artius Acquisition Inc. (“Artius”), a special purpose acquisition company, consummated the Merger Agreement and other Related Agreements (the “Merger Agreement”) dated February 16, 2021, by and among Artius, Zero Carbon Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Artius (“Merger Sub”), and Micromidas, Inc. a Delaware corporation (now known as Origin Materials Operating, Inc.). Pursuant to the terms of the Merger Agreement, a business combination between Artius and Legacy Origin was effected through the merger of Merger Sub with and into Legacy Origin, with Legacy Origin surviving as the surviving company and as a wholly-owned subsidiary of Artius (the “Merger” and, collectively with the other transactions described in the Merger Agreement, the “Business Combination”). On the Closing Date, Artius changed its name to Origin Materials, Inc. (collectively with its subsidiaries, the “Company”). For additional information on the Business Combination, please refer to Note 4, Business Combination, to these consolidated financial statements.

Risks and Liquidity	12 Months Ended
Risks and Liquidity	Dec. 31, 2021
Risks And Liquidity [Abstract]
Risks and Liquidity	Risks and Liquidity Prior to the Business Combination, the Company primarily financed its operations through the sale of convertible preferred stock, common stock, borrowings under convertible promissory notes and borrowings under loan agreements. The Company now believes that the Business Combination has provided substantial liquidity and that its $444.6 million of cash and cash equivalents, restricted cash, and marketable securities will enable it to fund its planned operations for at least twelve months from the issuance date of these consolidated financial statements. Beginning in March 2020, the COVID-19 pandemic and the measures imposed to contain this pandemic have disrupted and are expected to continue to impact the Company’s business. The magnitude of the impact of the COVID-19 pandemic on the Company’s productivity, results of operations and financial position, and its disruption to the Company’s business and battery development and timeline, will depend in part, on the length and severity of these restrictions and on the Company’s ability to conduct business in the ordinary course. We continue to monitor the rapidly evolving conditions and circumstances, as well as guidance from international and domestic authorities, including public health authorities, and we may need to take additional actions based on their recommendations. There is considerable uncertainty regarding the impact on our business stemming from current measures and potential future measures that could restrict access to our facilities, limit manufacturing and support operations and place restrictions on our workforce and suppliers. The measures implemented by various authorities related to the COVID-19 outbreak have caused us to change our business practices including those related to where employees work, the distance between employees in our facilities, limitations on in-person meetings between employees and with customers, suppliers, service providers and stakeholders, as well as restrictions on business travel to domestic and international locations or to attend trade shows, investor conferences and other events.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”).

Pursuant to the Merger Agreement, the merger between Merger Sub and Legacy Origin was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Artius was treated as the “acquired” company and Legacy Origin is treated as the acquirer for financial reporting purposes.

Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Legacy Origin issuing stock for the net assets of Artius, accompanied by a recapitalization. The net assets of Artius are stated at historical cost, with no goodwill or other intangible assets recorded.

Legacy Origin was determined to be the accounting acquirer based on the following predominant factors:

•the Company’s Board of Directors (the “Board”) and management are primarily composed of individuals associated with Legacy Origin;

•Legacy Origin’s senior management comprise the senior management roles of the Company and are responsible for the day-to-day operations;

•the Company assume the “doing business as” name of the Legacy Origin; and

•The intended strategy and operations of the Company continue Legacy Origin’s current strategy and operations as a carbon negative materials company with a mission to enable the world’s transition to sustainable materials.

The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Legacy Origin. The shares and corresponding capital amounts and losses per share, prior to the Business Combination, have been retroactively restated based on shares reflecting the Exchange Ratio (as defined below) established in the Business Combination.

Use of Estimates

The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to the valuation of common stock and valuation of convertible preferred stock warrants prior to the Business Combination, valuation of the earnout liability, valuation of assumed common stock warrants liability, carrying amount and useful lives of property and equipment and intangible assets, impairment assessments, marketable securities, stock-based compensation expense, probabilities of achievement of performance conditions on performance stock awards, among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.

Principles of Consolidation

The consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC and include the accounts of the Company and its wholly-owned subsidiaries, Origin Materials Canada Holding Limited, Origin Materials Canada Polyesters Limited, Origin Material Canada Pioneer Limited, Origin Materials Canada Research Limited, and Micromidas, Inc. (now known as Origin Materials Operating, Inc.). All intercompany accounts and transactions have been eliminated in consolidation.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and marketable securities accounts with a financial institution where, at times, deposits exceed federal insurance limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits.

Cash and Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts.

Restricted cash consists of cash held in a control account as collateral for the Company’s credit card services, escrow services, and standby letter of credit. These restricted cash balances have been excluded from cash and cash equivalents balance and are included within other current assets in the Consolidated Balance Sheets based on the respective maturity dates.

The Company has an escrow agreement for $1.3 million, whereby the funds would be used for construction and transportation services in connection with Origin 1. At December 31, 2021 and December 31, 2020, the escrow account had a balance of $0.3 million.

The Company has a standby letter of credit, whereby the funds may be used for the completion of work, services, and improvements in connection with Origin 1. The standby letter of credit matures and automatically renews in October of each year. At December 31, 2021 and December 31, 2020, the standby letter of credit was $0.2 million.

Cash, cash equivalents, and restricted cash consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	46,637	$	1,309
Restricted cash	$	490	$	565
Total cash, cash equivalents, and restricted cash	$	47,127	$	1,874

Marketable Securities

The Company’s investment policy is consistent with the definition of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component on the consolidated statements of comprehensive income until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair

value are assessed to determine what amount of the excess, if any, is caused by expected credit losses, as required by new accounting pronouncement, Accounting Standards Update No. 2016-13 (“ASU 2016-13”), discussed in further detail below. Expected credit losses on securities are recognized in other income (expense), net on the consolidated statements of operations and comprehensive loss, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive loss in the consolidated statement of redeemable convertible preferred stock and stockholders' equity. For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Interest on securities classified as available for sale is included as a component of interest income within other income (expense).

The nature of these financial instruments include instruments for which quoted prices are available but traded less frequently, instruments whose fair value has been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data, and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 2 financial instruments include agency mortgage-backed securities, corporate fixed income securities infrequently traded, and other securities, which primarily consist of sovereign debt, U.S. government agency securities, loans, and state and municipal securities.

Derivative Financial Instruments

The Company evaluated the stockholder convertible notes payable in accordance with ASC 815, Derivatives and Hedging and determined that the embedded components of these contracts qualify as a derivative to be separately accounted for as a liability. The Company records the fair value of the embedded components in accordance with ASC 815, Derivatives and Hedging. The fair value of the derivatives was calculated using a model that estimated the value that would be paid to transfer the liability in an orderly transaction between market participants at the measurement date. The fair value of the derivative liabilities is revalued on each balance sheet date with a corresponding gain or loss recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss).

The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the consolidated balance sheets.

Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized in the change in fair value of derivatives within other (income) expense. While the contract or notional amount is often used to express the volume of foreign currency derivative contracts, the amounts potentially subject to credit risk are generally limited to the amounts, if any, by which the counterparties’ obligations under the agreements exceed the obligations of the Company to the counterparties. The notional amount of foreign currency derivative contracts as of December 31, 2021 and 2020 was $63.7 million and $0.0 million, respectively.

Fair Value of Financial Instruments

The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3).

Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market.

The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. The fair value of debt approximates its carrying value based on prevailing market rates.

The fair values of the assumed common stock warrants which are publicly traded are level 1 inputs. The fair value of the assumed common stock warrants which are not publicly traded, cash equivalents, marketable securities, and foreign currency derivative contracts are level 2 inputs as the Company uses quoted market prices or alternative pricing sources and models utilizing observable market inputs. The earnout liability, derivative liability and redeemable convertible preferred stock warrant liability were estimated using Level 3 inputs.

Other Receivables

Other receivables consist of amounts due from foreign governmental entities related to the Canadian harmonized sales tax (HST) and goods and services tax (GST) for goods and services transacted in Canada, and amounts due from cash collateral held by others for foreign currency derivative contracts.

AgriScience Grant

In January 2019, the Company entered into an agreement in which it will participate in the AgriScience Program Cluster Component grant through the Canadian Agricultural Partnership, whereby the Company will receive reimbursements for eligible expenditures up to approximately $2.7 million (in Canadian dollars) through March 2022. Grants are received through reimbursements from the Canadian government and recognized, upon completion of scope of services on a quarterly basis. Grants are recognized as a reduction of property, plant, and equipment or expense based on the nature of the cost the grant is reimbursing. During the year ended December 31, 2021 and 2020 the Company received $0.0 million and $0.2 million in grants, recorded in other income, net on the Consolidated Statements of Operations and Comprehensive Income (Loss).

Property, Plant, and Equipment

Property, plant, and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. Existing useful lives range from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of their estimated useful lives or the lease term. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to operations. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts. Costs incurred to acquire, construct or install property, plant, and equipment during the construction stage of a capital project and costs capitalized in conjunction with major improvements that have not yet been placed in service are recorded as construction in progress, and accordingly are not currently being depreciated. The Company capitalizes interest cost incurred on funds used to construct property, plant and equipment. The estimated useful lives of assets are as follows:


Computer Equipment			3 years
Office Furniture			5 years
Machinery and Equipment			5 years
Leasehold Improvements			1-5 years

Intangible Assets

Intangible assets are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the respective assets, ranging from 7 to 15 years. The cost of servicing the Company’s patents is expensed as incurred. Upon retirement or sale, the cost of intangible assets is disposed of and the related accumulated amortization is removed from the accounts.

Impairment of Long-Lived Assets

The Company reviews its long-lived assets, including property, equipment, software and intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If indicators of impairment exist, management identifies the asset group which includes the potentially impaired long-lived asset, at the lowest level at which there are separate, identifiable cash flows. If the total of the expected undiscounted future net cash flows for the asset group is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. For the year ended December 31, 2021 and 2020, no impairment was identified.

Government Loans

Government loans are classified as a noncurrent liability and recorded at amortized cost. Forgiveness of the balances due is recorded through earnings and occurs when there is confirmation from the governmental authority that the Company has complied with the conditions for forgiveness attached to the loan.

Debt Issuance Costs

The costs incurred in connection with the issuance of debt obligations, principally financing and legal costs, are capitalized. These costs are accreted over the term of the debt using the interest method. During the year ended December 31, 2021 and 2020, accretion expense for debt issuance cost was $2.2 million and $0.1 million, respectively.

Redeemable Convertible Preferred Stock Warrants Liability

Free-standing warrants issued by Legacy Origin for the purchase of shares of its convertible preferred stock were classified as liabilities on the accompanying balance sheets at fair value using an Option-Pricing Model (“OPM”). Prior to the Business Combination, the liability recorded was adjusted for changes in the fair value at each reporting date and recorded as interest expense in the accompanying Consolidated Statements of Operations and Comprehensive Income (Loss). As a result of the Business Combination, the Legacy Origin warrants each converted into a warrant to purchase shares of the Company’s Common Stock converted at the Exchange Ratio. The fair value of the warrants upon consummation of the Business Combination (see Note 4), as adjusted based on the price of the underlying Common Stock, was reclassified to additional paid-in capital.

Assumed Common Stock Warrants Liability

The Company assumed 24,150,000 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Assumed Common Stock Warrants”) upon the Business Combination, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A Common Stock at an exercise price of at $11.50 per share. As of December 31, 2021, 24,150,000 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants.

The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”), and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the Assumed Common Stock Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves 50% or more of our Class A stockholders. Because not all of the voting stockholders need to participate in such tender offer or exchange to trigger the potential cash

settlement and the Company does not control the occurrence of such an event, the Company concluded that the Assumed Common Stock Warrants do not meet the conditions to be classified in equity. Since the Assumed Common Stock Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in the change in fair value of Assumed Common Stock Warrant liabilities within the Consolidated Statements of Operations and Comprehensive Income (Loss) at each reporting date. The Public Warrants were publicly traded and thus had an observable market price to estimate fair value, and the Private Placement Warrants were effectively valued similar to the Public Warrants, as described in Note 6.

Earnout Liability

The Company has recorded an earnout liability related to future contingent equity shares related to the Business Combination (Note 13). The Company recorded these instruments as liabilities on the Consolidated Balance Sheet at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date.

Leases

We have operating leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC 842, Leases. We recognize a right-of-use asset and lease liability for operating leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain.

Research and Development Cost

Costs related to research and development are expensed as incurred.

Stock-Based Compensation

The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including:

•Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term.

•Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor.

•Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future.

•Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate.

•Risk-free interest rate – The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with the same or substantially equivalent remaining term.

Income Taxes

Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely.

The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters as a component of income tax expense.

Functional Currency Translation

The functional currency of the Company’s wholly-owned subsidiaries is the Canadian dollar, whereby their assets and liabilities are translated at period-end exchange rates except for nonmonetary capital transactions and balances, which are translated at historical rates. All income and expense amounts of the Company are translated at average exchange rates for the respective period. Translation gains and losses are not included in determining net loss but are accumulated in a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the determination of net loss in the period in which they occur. These amounts are included in other income, net, of the Consolidated Statements of Operations and Comprehensive Income (Loss).

Comprehensive Income (Loss)

The Company’s comprehensive income or loss consists of net income or loss and other comprehensive income (loss). Foreign currency translation gains or losses and unrealized gains or losses on available-for-sale marketable debt securities are included in the Company’s other comprehensive income (loss).

Basic and Diluted Net Income (Loss) Per Share

Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net income (loss) per share calculation, the convertible preferred stock, common stock options, RSU awards, performance stock awards, convertible preferred stock warrants, common stock warrants, convertible notes, earnout shares, and Sponsor Vesting Shares (as defined below) are considered to be potentially dilutive securities. Basic and diluted net income (loss) per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. All series of the Company’s convertible preferred stock are considered to be participating securities because, in addition to cumulative dividends, all holders are entitled to receive a non-cumulative dividend on a pari passu basis in the event that a dividend is paid on the common stock. The two-class method requires income or loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income or loss for the period had been distributed. The holders of the convertible preferred stock do not have a contractual obligation to share in the Company’s losses. Accordingly, the Company’s net income (loss) is attributed entirely to common stockholders. For the periods presented that the Company has reported a net loss, diluted net loss per common share is the same as basic net loss per common share for those periods.

Reclassifications

Certain amounts in prior periods have been reclassified to conform with the report classifications of the year ended December 31, 2021, noting the Company has reflected the reverse recapitalization pursuant to the Business Combination for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity.

Segment Reporting

The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company has determined that its Co-Chief Executive Officers are the CODM. To date, the Company’s CODM has made such decisions and assessed performance at the Company level.

As of December 31, 2021 and December 31, 2020, the Company had $60.6 million and $45.4 million, respectively, of assets located outside of the United States.

Business Combination

12 Months Ended

Dec. 31, 2021

Business Combination and Asset Acquisition [Abstract]

Business Combination

On June 25, 2021, Artius and Micromidas, Inc. (now known as Origin Materials Operating, Inc., “Legacy Origin”) completed the Business Combination pursuant to the Merger Agreement with Legacy Origin surviving the merger as a wholly owned subsidiary of Artius, which became Origin Materials, Inc. Cash proceeds from the Business Combination totaled approximately $467.5 million, which included funds held in Artius’s trust account and the completion of the concurrent PIPE and Backstop Financing.

In accordance with the terms and subject to the conditions of the Merger Agreement, at the effective time of the Merger, (i) all shares of Legacy Origin’s Series A, Series B, and Series C Preferred Stock, and Common Stock (collectively, “Legacy Origin Stock”) issued and outstanding immediately prior to the effective time of the Merger were converted into the right to receive their pro rata portion of shares of Company Common Stock (the “Common Stock”) issued as Merger consideration (the “Merger Consideration”); (ii) holders of Legacy Origin’s Convertible Notes Payable, plus accrued interest also received shares of Company common stock; (iii) each option exercisable for Legacy Origin Stock that was outstanding immediately prior to effective time of the Merger was assumed and continues in full force and effect on the same terms and conditions as were previously applicable to such options, subject to adjustments to exercise price and number of shares Common Stock issuable upon exercise based on the final conversion ratio calculated in accordance with the Merger Agreement. Additionally, as part of the consideration transferred, stockholders of Legacy Origin and Artius were given the right to additional shares in the Company. These shares vest to the holder upon the share price of the Company reaching certain targets over a future period (“Earnout Shares”, see Note 13).

The Company accounted for the Business Combination as a reverse recapitalization, which is the equivalent of Legacy Origin issuing stock for the net assets of Artius, accompanied by a recapitalization, with Artius treated as the acquired company for accounting purposes. The determination of Artius as the “acquired” company for accounting purposes was primarily based on the fact that subsequent to the Business Combination, Legacy Origin will comprise all of the ongoing operations of the combined entity, a majority of the governing body of the combined company and Legacy Origin’s senior management will comprise all of the senior management of the combined company. The net assets of Artius were stated at historical cost with no goodwill or other intangible assets recorded. Reported results from operations included herein prior to the Business Combination are those of Legacy Origin. The shares and corresponding capital amounts and loss per share related to Legacy Origin’s outstanding convertible preferred stock and common stock prior to the Business Combination have been retroactively restated to reflect the conversion ratio established in the Merger Agreement (1.00 Legacy Origin share for approximately 2.11 shares of the Company, the Exchange Ratio).

In connection with the Business Combination, the Company incurred underwriting fees and other costs considered direct and incremental to the transaction totaling $36.7 million, consisting of legal, accounting, financial

advisory and other professional fees. These amounts are reflected within additional paid-in capital in the Consolidated Balance Sheet as of December 31, 2021.

PIPE Financing

Concurrent with the execution of the Business Combination, the Company entered into subscription agreements with certain investors (the “PIPE Investors”) pursuant to which the PIPE Investors subscribed for and purchased an aggregate of 20,000,000 shares of Common Stock for an aggregate purchase price of $200.0 million.

Backstop Agreement

Concurrent with the execution of the Business Combination, the Company entered into various subscription agreements (the “Subscription Agreements”) with certain current shareholders of the Company or their affiliates (collectively, the “Subscribers”), pursuant to which the Subscribers agreed, subject to certain conditions in the Subscription Agreements, to purchase an aggregate amount of 4,300,001 shares of common stock of the Company, par value $0.0001 per share (the “Subscription Shares”), at $10.00 per share.

Summary of Net Proceeds

The following table summarizes the elements of the net proceeds from the Business Combination at the date of acquisition (in thousands):


Cash—Trust Account (net of redemptions of $439 million)	$	260,448
Cash	60
Cash—PIPE & Backstop Financing	243,000
Non-cash net assets assumed from Artius	40
Less: Fair value of assumed common stock warrants	(83,370)
Less: Underwriting fees and other issuance costs paid prior to the date of acquisition	(34,773)
Additional Paid-in-Capital from Business Combination, net of issuance costs paid	$	385,405
Less: Non-cash net assets assumed from Artius	(40)
Add: Non-cash fair value of assumed common stock warrants	83,370
Add: Other issuance costs included in accounts payable and accrued liabilities	761
Less: Accrued liabilities extinguished through proceeds from Business Combination	(1,966)
Cash proceeds from the Business Combination	$	467,530

Summary of Shares Issued

The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination:


Artius shares outstanding prior to the Business Combination, including 4,500,000 Sponsor Vesting Shares			90,562,500
Less: redemption of Artius shares			(43,880,956)
Shares issued pursuant to the PIPE and Backstop Financing			24,300,001
Business Combination and PIPE Financing shares, including 4,500,000 Sponsor Vesting Shares			70,981,545
Conversion of Legacy Origin Series A preferred stock for common stock			33,783,099
Conversion of Legacy Origin Series B preferred stock for common stock			19,755,784
Conversion of Legacy Origin Series C preferred stock for common stock			6,286,349
Conversion of Legacy Origin convertible notes for common stock			2,049,212
Conversion of Legacy Origin common stock for common stock			2,838,041
Issuance of common stock upon exercise of warrants			5,554,440
Total shares of the Company common stock outstanding immediately following the Business Combination			141,248,470

Sponsor Vesting Shares were not included in the above schedule in previous interim period financial statements.

Recent Accounting Pronouncements	12 Months Ended
Recent Accounting Pronouncements	Dec. 31, 2021
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), to simplify the accounting for income taxes. The new guidance changes various subtopics of accounting for income taxes including, but not limited to, accounting for “hybrid” tax regimes, tax basis step-up in goodwill obtained in a transaction that is not a business combination, intraperiod tax allocation exception to incremental approach, ownership changes in investments, interim-period accounting for enacted changes in tax law, and year-to-date loss limitation in interim-period tax accounting. The Company early adopted the new standard as of January 1, 2021. The adoption of the standard had no material impact on the Company’s financial results. In February 2016, the FASB issued an ASU 2016-02, Leases (Topic 842), that amends the accounting guidance on leases. The standard establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The FASB also subsequently issued amendments to the standard, including providing an additional and optional transition method to adopt the new standard, described below, as well as certain practical expedients related to land easements and lessor accounting. We adopted this accounting standard effective January 1, 2021, using the optional transition method with no restatement of comparative periods. Therefore, the comparative information has not been adjusted and continues to be reported under ASC Topic 840. Our adoption of the new standard did not result in a cumulative effect adjustment to retained earnings. The adoption had a material effect on the Company’s consolidated financial statements. The most significant effects relate to (1) the recognition of new right-of-use assets and lease liabilities on our consolidated balance sheet for our building leases; and (2) providing significant new disclosures about our leasing activities. The Company also elected the package of practical expedients to leases that commenced before the effective date whereby we elected to not reassess the following: i.whether any expired or existing contracts contain leases; ii.the lease classification for any expired or existing leases; and iii.initial direct costs for any existing leases. Upon adoption of ASU 2016-02, we did not record right-of-use assets or lease liabilities for leases with an initial term of 12 months or less. Payments on those leases will be recognized on a straight-line basis over the lease term. We elected to combine lease and non-lease components on new or modified leases after adoption. Upon adoption as of January 1, 2021, we recorded $1.8 million in right-of-use assets and operating lease liabilities. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, and includes the Company's accounts receivable, certain financial instruments and contract assets. ASU 2016-13 results in more timely recognition of credit losses. Effective for our annual period as of January 1, 2021, the Company adopted the provisions and expanded disclosure requirements described in ASU 2016-13. The adoption of ASU 2016-13 was not material to the consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The FASB issued this update to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The main provisions of this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy: i.Information about the nature of the transactions and the related accounting policy used to account for the transactions ii.The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item iii.Significant terms and conditions of the transactions, including commitments and contingencies. The Company anticipates this will impact disclosures relating to their AgriScience Grant, PPP Loan, and Canadian Government Research and Development Program Liability. The amendments in this update are effective for the Company in the annual period beginning after December 15, 2021. Early application of the amendments is permitted. The Company has elected to adopt on January 1, 2022. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) Recognition of an acquired contract liability; and (2) Payment terms and their effect on subsequent revenue recognized by the acquirer. Specifically, the update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in an interim period. The Company does not believe the adoption of this standard will have a material effect on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The guidance is effective for fiscal years beginning on or after December 15, 2021, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company does not believe the adoption of this standard will have a material effect on its consolidated financial statements. In March 2020, the Financial Accounting Standards Board issued ASU No. 2020-04, Reference Rate Reform, which provides temporary optional guidance to companies impacted by the transition away from the London Interbank Offered Rate (“LIBOR”). The guidance provides certain expedients and exceptions to applying U.S. GAAP in order to lessen the potential accounting burden when contracts, hedging relationships, and other transactions that reference LIBOR as a benchmark rate are modified. The provisions of the new standard may be adopted as of the beginning of the reporting period when the election is made until December 31, 2022. The Company does not believe the adoption of this standard will have a material effect on its consolidated financial statements. The Company has elected to adopt on January 1, 2022.

Fair Value Measurement

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurement

The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:


	Fair Value as of December 31, 2021
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash, cash equivalents and restricted cash	$	47,127	$	—	$	—	$	47,127
Marketable securities	—		397,458		—		397,458
Derivative asset	—		202		—		202
Total fair value	$	47,127	$	397,660	$	—	$	444,787
Liabilities:
Assumed common stock warrants (Public)	$	35,983	$	—	$	—	$	35,983
Assumed common stock warrants (Private Placement)	—		16,877		—		16,877
Earnout liability	—		—		127,757		127,757
Derivative liability	—		103		—		103
Total fair value	$	35,983	$	16,980	$	127,757	$	180,720


	Fair Value as of December 31, 2020
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash, cash equivalents and restricted cash	$	1,874	$	—	$	—	$	1,874
Total fair value	$	1,874	$	—	$	—	$	1,874
Liabilities:
Redeemable convertible preferred stock warrants liability	$	—	$	—	$	19,233	$	19,233
Derivative liability	—		—		1,239		1,239
	$	—	$	—	$	20,472	$	20,472

The Company performs routine procedures such as comparing prices obtained from independent sources to ensure that appropriate fair values are recorded. The marketable securities are categorized as Level 2 instruments as the estimated fair value was determined based on the estimated or actual bids and offers of the marketable securities in an over-the-counter market on the last business day of the period. All of the Company’s cash, cash equivalents, restricted cash, marketable securities and foreign currency derivative contracts are classified within Level 1 or Level 2 because the Company’s cash, cash equivalents, restricted cash, marketable securities and foreign currency derivative contracts are valued using quoted market prices or alternative pricing sources and models utilizing observable market inputs. Because the transfer of Private Placement Warrants to anyone outside of certain permitted transferees of Artius Acquisition Partners LLC (the “Sponsor”) would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is consistent with that of a Public Warrant. Accordingly, the Private Placement Warrants are classified as Level 2 financial instruments.

The value of the redeemable convertible preferred stock warrants liability and the derivative liability are classified as Level 3 measurements under the fair value hierarchy, as these liabilities have been valued based on significant inputs not observable in the market.

As of December 31, 2021 and December 31, 2020, the carrying values of cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to their short-term nature.

Marketable Securities

The following table summarizes, by major security type, the Company’s marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. Amortized cost net of unrealized gain (loss) is equal to fair value as of December 31, 2021. The fair value as of December 31, 2021 is as follows:


	As of December 31, 2021
(in thousands)
Investments Classified as Marketable Securities	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Corporate bonds	$	274,939	$	100	$	(1,725)	$	273,314
Asset-backed securities	96,713		190		(199)		96,704
U.S. government and agency securities	20,235		—		(64)		20,171
Foreign government and agency securities	3,262		—		(19)		3,243
Municipal/provincial bonds and other	4,000		5		—		4,005
Total	$	399,149	$	295	$	(2,007)	$	397,437
Pending purchases and sales	21		—		—		21
Total marketable securities	$	399,170	$	295	$	(2,007)	$	397,458

Any realized gains and losses and interest income are included in other income on the consolidated statements of operations and comprehensive income (loss).

During the year ended December 31, 2021, we sold marketable securities for proceeds of $2,024.1 million and realized a gain of $0.2 million as a result of those sales. We regularly review our available-for-sale marketable securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The aggregate fair value of the marketable securities in unrealized loss position was $346.3 million as of December 31, 2021, none of which have been in the continuous unrealized loss for more than twelve months. The unrealized losses were attributable to changes in interest rates that impacted the value of the investments, and not increased credit risk. Accordingly, we have not recorded an allowance for credit losses associated with these investments.

The contractual maturities of the investments classified as marketable securities are as follows (in millions):



(in thousands)	Mature within one year		Mature after one year through two years		Mature over two years		Fair Value
Corporate bonds	$	92,559	$	134,199	$	46,556	$	273,314
Asset-backed securities	—		2,000		94,704		96,704
U.S. government and agency securities	—		7,995		12,176		20,171
Foreign government and agency securities	2,877		—		366		3,243
Municipal/provincial bonds and other	2,002		2,003		—		4,005
Total	$	97,438	$	146,197	$	153,802	$	397,437
Pending purchases and sales							21
Total marketable securities	$	97,438	$	146,197	$	153,802	$	397,458

Redeemable Convertible Preferred Stock Warrant Liability

In connection with the issuance of Series A preferred stock during 2012, the Company issued preferred stock warrants to purchase 1,000,000 shares of Series A preferred stock at an exercise price of $2.7233 per share. These warrants were initially exercisable any time within 10 years of issuance. In November 2019, as part of the Bridge

Notes issuance (see Note 11), these Series A preferred stock warrants had their contractual exercise period extended 10 years to October 2032.

In connection with the issuance of Series A preferred stock during 2015, the Company issued preferred stock warrants to purchase 1,134,653 shares of Series A preferred stock at an exercise price of $2.7233 per share. These warrants were initially exercisable any time within 10 years of issuance. In November 2019, as part of the Bridge Notes issuance (see Note 11), these Series A preferred stock warrants had their contractual exercise period extended 10 years to October 2035.

In connection with the issuance of Series A preferred stock during April 2016, the Company issued a preferred stock warrant to purchase 122,400 shares of Series A preferred stock at an exercise price of $2.7233 per share. This warrant is exercisable and expires in April 2036.

In connection with the issuance of convertible promissory notes in 2016, the Company in 2016 and 2017 issued preferred stock warrants to purchase 331,927 and 35,412 shares, respectively, of Series B preferred stock at an exercise price of $7.486 per share. These preferred stock warrants are exercisable and expire from June through July 2026 and June 2036 through January 2037.

At December 31, 2020, the fair value of the preferred stock warrants was determined using the probability-weighted expected return method which estimates the fair value of the warrants through an analysis of future values for the Company, assuming various future outcomes. A Black-Scholes option pricing model (BSM) is utilized in this method, to the extent necessary, based on current conditions. A summary of key assumptions in the BSM for determining the fair value of redeemable convertible preferred stock warrants include:


	December 31, 2020
Expected life (years)	3.00
Risk-free interest rate	0.17	%
Expected volatility	70.00	%
Dividend yield	0	%

The preferred stock warrants were reclassified to equity through the closing of the Business Combination (see Note 4).

Derivative Asset and Liabilities

Beginning in the year ended December 31, 2021, the Company entered into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized as other income (expense). During the year ended December 31, 2021, the Company recognized a net gain of $0.1 million on the fair value adjustment of the foreign currency derivative contracts.

The following table sets forth a summary of the activities of the Company’s redeemable convertible preferred stock warrant liability and embedded components of the stockholder convertible notes payable, which represents a

recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs:


Redeemable Convertible Preferred Stock Warrant	Years Ended December 31,
(in thousands)	2021		2020
Beginning warrant liability balance	$	19,233	$	735
Change in fair value of warrants liability	35,034		18,498
Reclassification to APIC upon recapitalization	(54,267)		—
Ending warrant liability balance	$	—	$	19,233

Embedded Derivative - Stockholder Convertible Notes Payable	Years Ended December 31,
(in thousands)	2021		2020
Beginning derivative liabilities balance	$	1,238	$	150
Change in fair value	(1,238)		1,088
Ending derivative liabilities balance	$	—	$	1,238

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property, Plant and Equipment

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Property, plant, and equipment consisted of the following:


(in thousands)	December 31, 2021		December 31, 2020
Land	$	912	$	39
Pilot plant	5,517		5,237
Lab equipment	2,227		1,958
Machinery and equipment	655		655
Computer and other equipment	388		295
Construction in process	55,026		43,962
	64,725		52,146
Less accumulated depreciation and amortization	(7,540)		(7,042)
Total property, plant, and equipment, net	$	57,185	$	45,104

For the year ended December 31, 2021 and 2020, depreciation expense totaled $0.5 million.

At December 31, 2021 and December 31, 2020, the Company capitalized $0.9 million and $0.7 million, respectively, of interest cost into Origin 1. At December 31, 2021 and December 31, 2020 a cumulative translation adjustment of $(0.1) million and $0.9 million, respectively, is included in total property, plant, and equipment as a result of foreign currency transaction gains and losses.

Intangible Assets

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible assets consisted of the following:


(in thousands)	December 31, 2021		December 31, 2020
Patents	$	432	$	430
Less accumulated amortization	(217)		(172)
	$	215	$	258

The weighted average useful life of the intangible assets was 9.87 years. For the year ended December 31, 2021 and 2020, amortization expense was $0.0 million.

Consortium Agreement	12 Months Ended
Consortium Agreement	Dec. 31, 2021
Pledged Financial Instruments, Not Separately Reported, Securities, by Type of Agreement [Abstract]
Consortium Agreement	Consortium Agreement The Company has entered into consortium agreements with counterparties to collaborate on development of a process to commercialize bio-based, decarbonizing materials for application on an industrial scale at a competitive price. Under the consortium agreement, the Company received $0.5 million. The agreements expire once performance of the research and development program has been completed. At the time the consortium agreements were entered into, several of the counterparties were related parties (Note 11). In 2020, an additional counterparty, that is an unrelated party, was added to the consortium agreement. During the year ended December 31, 2021 and 2020, the Company received $0.5 million and $0.6 million, respectively, under the consortium agreement which was recorded as other income, net in the Consolidated Statements of Operations and Comprehensive Income (Loss).

PPP Loan	12 Months Ended
PPP Loan	Dec. 31, 2021
Debt Disclosure [Abstract]
PPP Loan	PPP Loan In April 2020, the Company executed a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $0.9 million under the Paycheck Protection Program (the “PPP Loan”). The Paycheck Protection Program (or “PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). The Loan has been made through First Republic Bank (the “Lender”). The PPP Loan had a two-year term and bore interest at a rate of 1.00% per annum, accruing upon funding. Unless the PPP Loan is forgiven, the Company was required to make monthly payments of principal and interest to the Lender. The Company did not intend to seek forgiveness of the PPP loan. The PPP Note contained customary events of default relating to, among other things, payment defaults, providing materially false and misleading representations to the SBA or Lender, or breaching the terms of the PPP Loan documents. The occurrence of an event of default may result in the immediate repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment. Under the terms of the CARES Act, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The PPP Loan was paid in full during the year ended December 31, 2021.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Consortium Agreements In December 2016, the Company entered into a consortium agreement (Note 9) with two Legacy Origin Series B preferred stock investors to collaborate on development of a process to commercialize bio-based, decarbonizing materials for application on an industrial scale at a competitive price. Under the consortium agreement, the Company received $0.5 million. The agreement expires once performance of the research and development program has been completed. In August 2018, the agreement was amended, whereby a Legacy Origin Series C preferred stock investor (the “Legacy Origin Series C Investor”, and collectively with the two Legacy Origin Series B investors, the “Legacy Origin Investors”) was added to the agreement and committed to invest $1.5 million of research and development in the consortium. As of December 31, 2021, the Legacy Origin Series C Investor had not invested any funds in the consortium. Offtake Agreements The Company maintains four separate offtake supply agreements (the “Offtake Agreements”). All are with Legacy Origin stockholders or affiliates of Legacy Origin stockholders. Pursuant to the Offtake Agreements, the Company will construct manufacturing plants with specific capacity and product quality requirements within certain timeframes for the manufacture of product for sale to the counterparties to the agreements, and the counterparties will make minimum annual purchases at a set price, subject to adjustments, all as defined in the agreements. The Offtake Agreements allow the customers to terminate the agreements if specified construction and product delivery requirements are not satisfied. For example, under two of these agreements, if Origin 1 has not commenced commercial operation by December 31, 2021 or Origin has not delivered specified product volume from Origin 1 by September 30, 2022, then the customer may terminate the agreement and any outstanding secured promissory notes resulting from advance payments made to Origin will become due immediately (see Note 12). These outstanding obligations, together with accrued interest, totaled an aggregate of $10.9 million and $10.7 million as of December 31, 2021 and December 31, 2020 respectively (see Note 12). These agreements also require the Company to pay liquidated damages up to an aggregate of $0.9 million if Origin 1 has not commenced commercial operation by December 31, 2020 or the Company has not delivered specified product volume from Origin 1 by September 30, 2021. In November 2021, one counterparty agreed to waive compliance with the milestones and their right to liquidated damages until June 30, 2022 and in December 2021 the other counterparty agreed to waive compliance with the milestones and their right to liquidated damages until March 31, 2022. A third offtake agreement is terminable by the customer if commercial operation or delivery of product from Origin 1 has not occurred by December 31, 2022. The Company believes enforcement of the liquidated damages provisions was not probable and expects to secure amendments to these offtake agreements pursuant to its ongoing discussions with these customers. However, the Company cannot guarantee that it will be successful in amending these offtake agreements. One of the Offtake Agreements provides the counterparty the option, exercisable within 1 year of the first delivery of product from Origin 1, to enter into a contract to purchase a range of quantities of product from Origin 2 for a maximum term of 10 years. If the option is exercised and the Company directly or indirectly constructs Origin 2, the Company must either enter into an agreement with the counterparty within 90 days or pay a fee. There are no impacts to these consolidated financial statements from this stipulation. Stockholder Convertible Notes Payable In November 2019, the Company entered into secured convertible note agreements (“Bridge Notes”) with certain Legacy Origin preferred stockholders, whereby the Company can borrow up to $6.0 million. The Bridge Notes bore an annual interest rate of 10% and matured on March 31, 2021, unless converted. If the Company issues shares of a new series of preferred stock prior to maturity, the outstanding principal and unpaid accrued interest will convert at 70% of the per share price of the new series of preferred stock. Upon a liquidation event, as defined in the agreements, the Company would be required to repay purchasers in cash an amount equal to 200% of the outstanding principal amount plus the outstanding principal and accrued interest. The Bridge Notes were collateralized by substantially all of the Company’s assets. At December 31, 2020, there was $3.2 million, outstanding on the Bridge Notes. The conversion and liquidation features were deemed to be derivatives under ASC 815 (see Note 6) and separately measured and recognized from the Bridge Notes through a debt discount. In January of 2021, the Company amended the Bridge Notes to extend the maturity date from March 31, 2021 to September 30, 2021. The amendment also added a SPAC transaction to the conversion provision such that the Bridge Notes convert if the Company issues at least $50 million of shares of a new series of preferred stock or closes a SPAC transaction (each a “Qualified Financing”) prior to maturity. In a Qualified Financing that is a preferred stock issuance, the notes convert at 70% of the cash price paid per share for the preferred shares. In a Qualified Financing that is a SPAC transaction, the notes convert at the lesser of (i) 70% of the per share value attributed to the shares of the Company’s common stock as set forth in the Merger Agreement or (ii) the per share value that would be attributed to the Company’s common stock assuming a pre-transaction valuation of the Company in connection with the SPAC transaction of $700 million. These notes fully converted into the Company common stock upon consummation of the Business Combination (see Note 4). In February of 2021 the Company issued $10.0 million of new, unsecured convertible notes (the “Convertible Notes”). The Convertible Notes bore an annual interest rate of 8% and mature on September 30, 2021, unless converted. If the Company issues at least $50 million worth of shares of a new series of preferred stock prior to maturity or closes a SPAC transaction (each a “Qualified Financing”), the outstanding principal and unpaid accrued interest will convert at 80% of the per share price of the new series of preferred stock or, in the case of a SPAC transaction, at 80% of the per share value attributed to the shares of the Company’s common stock as set forth in the Merger Agreement. Upon a Change of Control (other than a Qualified Financing), as defined in the Convertible Notes, the Company will repay purchasers in cash an amount equal to the outstanding principal and accrued interest plus a repayment premium equal to 100% of the outstanding principal amount of the notes. Debt issuance costs are recorded against the outstanding payable balance. These notes fully converted into the Company common stock upon consummation of the Business Combination (see Note 4). Legacy Stockholder Note In November 2016, the Company received a $5.0 million prepayment from a Legacy Origin stockholder for product from Origin 1 pursuant to an Offtake Agreement (see Note 11). The prepayment was to be credited against the purchase of products over the term of the Offtake Agreement. The prepayment was secured by a promissory note (the “Promissory Note”) to be repaid in cash in the event that the prepayment could not be credited against the purchase of product, for example, if Origin 1 was never constructed. The Promissory Note was collateralized substantially by Origin 1 and other assets of Origin Material Canada Pioneer Limited. In May 2019, the Company and legacy stockholder amended the Offtake Agreement and Promissory Note. The amendment added accrued interest of $0.2 million to the principal balance of the prepayment and provided for the prepayment amount to be repaid in three annual installments rather than being applied against the purchase of product from Origin 1. The Promissory Note would bear interest at 3.50% per annum and be repaid in three installments of $2.2 million, $2.1 million, and $2.1 million (inclusive of accrued but unpaid interest) on December 20, 2024, December 19, 2025, and December 18, 2026, respectively. At December 31, 2021 and December 31, 2020, the total debt principal outstanding was $5.2 million. Legacy Related Party Other Liabilities, Long-term In November 2016, the Company received a $5.0 million prepayment from a legacy stockholder for product from Origin 1 pursuant to an Offtake Agreement (see Note 11). The prepayment is to be credited against the purchase of products from Origin 1 over the term of the Offtake Agreement. Specifically, repayment is effected by applying a credit to product purchases each month over the first five years of operation of Origin 1 up to $7.5 million, which is equal to 150% of the prepayment amount. If product purchases are not sufficient to recover the advances, the application of the credit to purchases as payment of the advances will continue until fully repaid. The prepayment is secured by a note to be repaid in cash in the event the prepayment cannot be credited against the purchase of product, for example, if Origin 1 is never constructed. The note is collateralized substantially by Origin 1 and other assets of Origin Material Canada Pioneer Limited. If repaid in cash, the note bears an annual interest rate of the three-month London Interbank Offered Rate (LIBOR) plus 0.25% (0.38% at December 31, 2021) and matures five years from the commercial operation date of Origin 1. At December 31, 2021 and December 31, 2020 the total note principal outstanding was $5.1 million and accrued interest outstanding was $0.1 million.

Other Liabilities, Long-term	12 Months Ended
Other Liabilities, Long-term	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Other Liabilities, Long-term	Other Liabilities, Long-termIn September 2019, the Company entered into a $5.0 million prepayment agreement with a counterparty for the purchase of products from Origin 2. The prepayment is to be made in two equal installments: the first $2.5 million was in October 2019 and the remaining $2.5 million is due within 30 days of the customer confirming that a sample from Origin 1 meets the customer’s specifications. The Company and customer agreed to work in good faith to execute an Offtake Agreement, the agreed terms of which are set forth in the prepayment agreement, whereby 100% of the prepayment will be applied against future purchases. The prepayment agreement provides the customer a capacity reservation of up to a specified annual volume of product from Origin 1 for a term of ten years, pursuant to the terms of an Offtake Agreement. At December 31, 2021 and December 31, 2020, the total amount outstanding on this agreement was $2.5 million.

Earnout Liability	12 Months Ended
Earnout Liability	Dec. 31, 2021
Earnout Liability Disclosure [Abstract]
Earnout Liability	Earnout LiabilityAs additional consideration for the Merger, within ten (10) Business Days after the occurrence of a Triggering Event, the Company shall issue or cause to be issued to each Legacy Origin and Artius Holder the number of shares of the Company Class A Common Stock equal to the product of (i) the number of shares of Company Common Stock, Company Series A Preferred Stock, Company Series B Preferred Stock, Company Series C Preferred Stock, and the net number of shares of Company Capital Stock that would be issuable in respect of Vested Company Options in the event such options were exercised (on a net exercise basis with respect to only the applicable exercise price, immediately prior to the Closing and settled in the applicable number of shares of Company Common Stock, rounded down to the nearest whole share) held by such Legacy Origin Holder as of immediately prior to the Effective Time; and (ii) the Earnout Exchange Ratio (such issued shares of Artius Class A Common Stock, collectively, the “Earnout Shares”). Notwithstanding anything to the contrary herein, in no event shall Artius be required to issue more than 25,000,000 Earnout Shares in the aggregate. A Triggering Event is defined as the following: (a)the volume weighted average price of Common Stock ("VWAP") equaling on exceeding $15.00 for ten (10) consecutive trading days during the three (3) year period following the Closing Date; (b)the VWAP equaling or exceeding $20.00 for ten (10) consecutive trading days during the four (4) year period following the Closing Date; or (c)the VWAP equaling or exceeding $25.00 for ten (10) consecutive trading days during the five (5) year period following the Closing Date. A Sponsor Letter Agreement was delivered in connection with the Merger such that 4,500,000 million of the shares held by Sponsor (“Sponsor Vesting Shares”) shall be subject forfeiture based on the same vesting requirements as the Earnout Shares. These shares shall not be transferred prior to the date in which they vest. Dividends and other distributions with respect to Sponsor Vesting Shares shall be set aside by the Company and shall be paid to the Sponsor upon the vesting of such Sponsor Vesting Shares. The Company evaluated the Earnout Liability under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”), and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, there are contingent exercise provisions and settlement provisions that exist. Holders may receive differing amounts of shares depending on the company’s stock price or the price paid in a change of control. It is noted that all remaining shares would be issuable (or the forfeiture provisions would lapse) upon any change of control involving the company and all remaining shares would be issuable (or the forfeiture provisions would lapse) upon a bankruptcy or insolvency of the company. This means that settlement is not solely impacted by the share price of the Company (that is, the share price observed in or implied by a qualifying change-in-control event), but also by the occurrence of a qualifying change-in-control event. This causes the arrangement to not be indexed to the Company’s own shares and liability classification is appropriate. The Company recorded these instruments as liabilities on the consolidated balance sheet at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date. The earnout liability was fair valued using a Monte Carlo open-ended model. The inputs used for the model were a dividend yield of 0%, volatility of 82%, and interest rate of 1.18%. At December 31, 2021 and December 31, 2020 the balance of the earnout liability was $127.8 million and $0.0 million, respectively. A gain of $75.5 million was recorded for the year ended December 31, 2021 Consolidated Statement of Operations and Comprehensive Income (Loss) for the change in the fair market value of the liability.

Canadian Government Research and Development Program Liability	12 Months Ended
	Dec. 31, 2021
Research and Development [Abstract]
Canadian Government Research and Development Program Liability	Canadian Government Research and Development Program Liability In April 2019, the Company entered into a contribution agreement related to the research and development and construction associated with the operation of Origin 1 in which the Company will participate in a Canadian government research and development program (the “R&D Agreement”). Pursuant to the R&D Agreement, the Company will receive funding for eligible expenditures through March 31, 2023 up to the lesser of approximately 18.48% of eligible costs and $23.0 million (in Canadian dollars). The funding will be repaid over 15 years after completion of Origin 1, commencing no sooner than the third fiscal year of consecutive revenues from a commercial plant, but no later than the fifth year following the earlier of (i) the year in which the Company completes construction of Origin 1 or (ii) March 2023. The maximum amount to be repaid by the Company under the R&D Agreement is 1.25 times the actual funding received, subject to the following repayment ceiling formula. Repayment of the funding will be reduced by 50% if the Company begins construction before December 31, 2024 of one or more commercial plants that operate in Canada, with costs exceeding $500 million (in Canadian dollars), and the plants being constructed and operational within 30 months of the final investment decision, as defined in the R&D Agreement. Once begun, repayments will be paid annually by April of each year through March 31, 2037. Payments will be determined by a formula of the funded amount based on the fiscal year gross business revenue, as defined in the R&D Agreement. At December 31, 2021 and December 31, 2020, the Company recorded a liability for the amount received of $6.8 million and $6.2 million, respectively.

Assumed Common Stock Warrants	12 Months Ended
Assumed Common Stock Warrants	Dec. 31, 2021
Assumed Common Stock Warrants [Abstract]
Assumed Common Stock Warrants	Assumed Common Stock Warrants As of December 31, 2021 there are 35,476,667 warrants outstanding. As part of Artius’s initial public offering, 24,150,000 Public Warrants were sold. The Public Warrants entitle the holder thereof to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustments. The Public Warrants may be exercised only for a whole number of shares of Common Stock. No fractional shares will be issued upon exercise of the warrants. The Public Warrants will expire on June 25, 2026 at 5:00p.m., New York City time, or earlier upon redemption or liquidation. The Public Warrants are listed on the Nasdaq under the symbol “ORGNW”. The Company may redeem the Public Warrants when exercisable, in whole and not in part, at a price of $0.01 per warrant, so long as the Company provides not less than 30 days’ prior written notice of redemption to each warrant holder, and if, and only if, the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date the Company sends the notice of redemption to the warrant holders. Simultaneously with Artius’s initial public offering, Artius consummated a private placement of 11,326,667 Private Placement Warrants with the Sponsor. The Private Placement Warrant is exercisable for one share of Class A Common Stock at a price of $11.50 per share, subject to adjustment. The Private Placement Warrants are identical to the Public Warrants, except that: (1) the Private Placement Warrants and the shares of Class A Common Stock issuable upon exercise of the Private Placement Warrants are not transferable, assignable or salable until the earliest to occur of: (i) 365 days after the date of the Closing; (ii) the first day after the date on which the closing price of the Public Shares (or any successor securities thereto) equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the date of the Closing; or (iii) the date on which Artius completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Artius’s Public Shareholders having the right to exchange their Public Shares (or any successor securities thereto) for cash, securities or other property, subject to certain limited exceptions, (2) the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except if the reference value equals or exceeds $10.00 and is less than $18.00 (as described above), so long as they are held by the initial purchasers or their permitted transferees, and (3) the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will be entitled to registration rights. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable under all redemption scenarios by the Company and exercisable by such holders on the same basis as the Public Warrants. The Company concluded the Public Warrants and Private Placement Warrants, or Assumed Common Stock Warrants, meet the definition of a derivative under ASC 815 and are recorded as liabilities. Upon consummation of the Business Combination, the fair value of the Assumed Common Stock Warrants was recorded on the Consolidated Balance Sheet. The fair value of the Assumed Common Stock Warrants was remeasured on the December 31, 2021 Consolidated Balance Sheet at $52.9 million with a gain of $30.5 million recorded in the year ended December 31, 2021 Consolidated Statement of Operations and Comprehensive Income (Loss).

Stockholders' Equity

12 Months Ended

Dec. 31, 2021

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Stockholders’ EquityAs of December 31, 2021, 1,010,000,000 shares, $0.0001 par value per share are authorized, of which, 1,000,000,000 shares are designated as Common Stock and 10,000,000 shares are designated as Preferred Stock.

Common Stock

Holders of the common stock are entitled to dividends when, as, and if, declared by the Board, subject to the rights of the holders of all classes of stock outstanding having priority rights to dividends. As of December 31, 2021, the Company had not declared any dividends. The holder of each share of Common Stock is entitled to one vote. There were 141,301,569 (including 4,500,000 Sponsor Vesting Shares not indexed to equity) and 62,545,275 shares of common stock outstanding as of December 31, 2021 and December 31, 2020, respectively.

Employee Stock Purchase Plan

The Company maintains an Employee Stock Purchase Plan (ESPP). Initially, the maximum number of shares of our Common Stock that may be issued under the ESPP will not exceed 1,846,710. Additionally, the number of shares of our Common Stock reserved for issuance under the ESPP will automatically increase on January 1st of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by the lesser of (1) one percent (1%) of the fully-diluted shares of our Common Stock on December 31st of the preceding calendar year, (2) the number of shares of our Common Stock equal to two hundred percent (200%) of the ESPP’s initial share reserve, or (3) such lesser number of shares as determined by our board of directors. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP.

The ESPP permits participants to purchase shares of our Common Stock with the purchase price of the shares at 85% of the lower of the fair market value of our Common Stock on the first day of an offering or on the date of purchase.

To date no stock has been offered or issued to employee's under the ESPP.

Equity Incentive Plans

The Company maintains the following equity incentive plans: the 2010 Stock Incentive Plan, the 2020 Equity Incentive Plan and the 2021 Equity Incentive Plan, each as amended (together, the “Stock Plans”). Upon closing of the Business Combination, awards under the 2010 Stock Incentive Plan and 2020 Equity Incentive Plan were converted at the Exchange Ratio and the 2021 Equity Incentive Plan was adopted and approved. As of December 31, 2021, there were 18,467,109 shares of common stock reserved under the Stock Plans. Origin may grant a wide variety of equity securities under the Stock Plans, including incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance stock awards, and other awards. At December 31, 2021, the Company has granted incentive stock options, RSU awards, and performance awards. Under the Stock Plans, options must be issued at prices no less than the estimated fair value of the stock on the date of grant and are exercisable for a period not exceeding 10 years from the date of grant. Options granted to employees under the Stock Plans generally vest 25% one year from the vesting commencement date and 1/36th per month thereafter, although certain arrangements call for vesting over other periods. Options granted to non-employees under the Stock Plan vest over periods determined by the Board (generally immediate to four years). RSU awards granted to employees under the Stock Plans require a service period of three years and generally vest 33.3% annually over the three-year service period. Under the Stock Plans, the fair value of RSU awards and performance awards are determined to be the grant date closing stock price. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. At December 31, 2021, the Company determined the performance conditions were not probable of being met, therefore no stock compensation was accrued.

The following tables summarize the activity under the Stock Plans:


	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance at December 31, 2019	2,205,015	$	0.36	3.89
Granted	6,296,302	$	0.14
Exercised	(2,912)	$	0.37
Forfeited / canceled	(275,695)	$	0.43
Balance at December 31, 2020	8,222,710	$	0.19	8.30
Granted	—
Exercised	(171,118)	0.42
Forfeited / canceled	(158,735)	0.14
Balance as of December 31, 2021	7,892,857	$	0.19	7.31
Vested and expected to vest at December 31, 2021	7,872,978

During the year ended December 31, 2021, the Company did not grant any stock options.

As of December 31, 2021 and December 31, 2020, there were 7,667,247 and 10,244,399 awards, respectively, available for grant under the Stock Plans. As of December 31, 2021 and December 31, 2020 there were 4,130,184 and 2,150,941 exercisable options, respectively. The aggregate intrinsic value of options vested and expected to vest at December 31, 2021 is $49,260,254. As of December 31, 2021, the Company had stock-based compensation of $6.6 million related to unvested stock options not yet recognized that are expected to be recognized over an estimated weighted average period of 2.6 years.

The Company issued 2,920,732 of performance and market-based stock options during 2020. During the quarter ended March 31, 2021, the Company modified the vesting schedule of 529,119 of these performance and market based stock options such that vesting at 1/48th per month would commence upon signing of the Business Combination. The Company entered into the Merger Agreement on February 16, 2021 resulting in the commencement of expense recognition related to these 529,119 options during the quarter ended March 31, 2021. During the year ended December 31, 2021, stock compensation expense related to these performance and market based stock options was $2.9 million. For the remaining 2,391,613 performance and market-based stock options, expense commenced on the close date of the Merger, June 25, 2021, as that is the date when the performance condition was achieved.

RSU award and performance award activity for the year ended December 31, 2021 is as follows:


	Restricted Stock Outstanding
	Outstanding	Weighted-average grant date fair value
Balance at December 31, 2020	—
Granted - RSU awards	769,505	7.34
Granted - performance awards	2,137,500	7.35
Balance at December 31, 2021	2,907,005	7.35
Expected to vest	769,505

The RSU awards, which upon vesting entitles the holder to be issued on a future date the number of shares of common stock that is equal to the number of restricted stock units subject to the RSU award. As of December 31, 2021, the performance conditions for the granted performance awards were not probable of being met, therefore no performance award stock compensation has been recorded. No RSU awards or performance awards vested during fiscal 2021 and 2020. As of December 31, 2021, the Company had unrecognized stock-based compensation of $5.4

million related to unvested RSU awards that are expected to be recognized over an estimated weighted average period of 2.9 years.

For the year ended December 31, 2021 and 2020, stock compensation expense of $5.8 million and $1.6 million, respectively, was recognized in general and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income (Loss). During the year ended December 31, 2021 and 2020 stock compensation expense of $1.3 million and $0.1 million, respectively, was recognized in research and development expenses on the Consolidated Statements of Operations and Comprehensive Income (Loss). Total remaining compensation expense to be recognized under the Stock Plan is $7.3 million as of December 31, 2021 and will be amortized on a straight-line basis over the remaining vesting periods of approximately four years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Income (loss) before provision for income taxes consisted of the following:


(in thousands)	December 31, 2021		December 31, 2020
United States	$	43,645	$	(29,162)
International	(1,554)		(1,141)
Income (loss) before provision for income taxes	$	42,091	$	(30,303)

The federal and state income tax expense is summarized as follows:


(in thousands)	December 31, 2021		December 31, 2020
Current
Federal	$	—	$	—
State	3		2
International	—		—
Total current tax expense	3		2
Deferred
Federal	—		—
State	—		—
International	—		—
Total deferred tax expense	—		—

Total tax expense	$	3	$	2

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and operating losses and tax carryforwards.

The tax effects of significant items comprising the Company's deferred taxes are as follows:


(in thousands)	December 31, 2021		December 31, 2020
Deferred tax assets
Net operating loss carryforwards	$	24,899	$	18,400
Available for Sale Securities	390		—
Lease liability	341		—
Other	230		149
Fixed assets and intangibles	89		114
Total deferred tax assets	25,949		18,663

Deferred tax liabilities
ROU asset	(344)		—
Total deferred tax liabilities	(344)		—

Valuation allowance	(25,605)		(18,663)
Net deferred taxes	$	—	$	—

ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is more likely than not. Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward period. Because of the Company's recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.

The valuation allowance increased by $6.9 million and $1.9 million for the years ended December 31, 2021 and 2020, respectively.

At December 31, 2021, we had federal net operating loss carryforwards of approximately $97.8 million to offset future federal taxable income, with $44.9 million available through 2037 and $52.9 million available indefinitely. We also had state net operating loss carryforwards of approximately $36.8 million that may offset future state taxable income through 2041. We also had foreign net operating loss carryforwards of approximately $6.7 million that may offset future foreign taxable income through 2041.

At December 31, 2021, the Company has research and experimentation credit carryforwards of $— million for foreign tax purposes that expire after 2038.

The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows:


	December 31, 2021		December 31, 2020
Statutory rate	21.0	%	21.0	%
State tax	(1.3)		(0.1)
Warrants, BCF, and other equity items	(33.3)		(13.1)
Valuation allowance	15.6		(6.4)
Other	(0.2)		(0.1)
Foreign rate differential	(0.2)		0.2
Stock-based compensation	(1.6)		(1.5)
Total	—	%	—	%

Under certain provisions of the Internal Revenue Code of 1986, as amended, a portion of the federal and state net operating loss carryforwards may be subject to an annual utilization limitation as a result of a change in ownership of the Company. Federal and California tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (“Section 382”). The Company believes a change in ownership, as defined by Section 382, has occurred but a formal study has not been completed. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes.

There were no unrecognized tax benefits in the years ended December 31, 2021 and 2020. The Company files income tax returns in the United States, various US states, and Canada. All tax years remain open in all jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other foreign jurisdictions. The Company does not anticipate any significant changes within 12 months of this reporting date of its uncertain tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Leases

The Company leases office space and research and development space in Sacramento, California and Sarnia, Ontario under noncancelable lease agreements and leases various office equipment, warehouse space, and temporary fencing. The operating leases have remaining lease terms of one to nine years. Certain operating leases contain options to extend the lease. The Company included the periods covered by these options as we are reasonably certain to exercise the options for all leases. For leases with the option to extend on a month-to-month basis after the defined extension periods, the Company is reasonably certain to extend for the same term as related leases. As such, lease terms for all leased assets located at the same locations have the same end dates. Rent deposits relating to leases are included within other long-term assets on the Consolidated Balance Sheets.

During 2021, the Company entered into a seven-year lease agreement for office space in Sacramento, California and recorded an operating lease ROU asset of approximately $0.9 million. Also in 2021, the Company entered into an 18-month lease agreement for office space in Sarnia, Ontario and recorded an operating lease right-of-use asset of approximately $0.1 million. The Company also entered into certain other operating leases during 2021 which were not individually or in aggregate material to the Company’s consolidated financial statements. During 2021, the Company amended two of its existing office leases in Sacramento, California. The new agreement increased the lease payments and extended the lease agreement through October 2028.

The Company elected the accounting policy election to account for lease and nonlease components as a single lease component for all asset classes. Further, the Company elects to recognize lease payments on short-term leases in profit or loss on straight-line basis over the lease term for all asset classes, excluding such leases from recognition requirements under Topic 842.

The components of lease cost were as follows:


(in thousands)	December 31, 2021




Operating lease cost	$	324
Variable lease cost	68
Total lease cost	$	392

Other information related to leases is as follows:


(in thousands)	December 31, 2021

Operating lease ROU asset (included within Lease right-of-use asset)	$	1,782

Weighted average remaining lease term (in years):

Operating leases	7.44
Weighted average discount rate:

Operating leases	2.8		%


(in thousands)	December 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	271


ROU assets obtained in exchange for operating lease liabilities	$	2,062

To calculate the ROU assets and liabilities, the Company uses the discount rate implicit in lease agreements when available. When the implicit discount rates are not readily determinable, the Company uses the incremental borrowing rate, determined as of the date of adoption for Topic 842. This rate was determined for individual leases based on available information regarding jurisdiction, lease term, and asset class. Further, the interest environment was considered, including analysis of benchmark rates from promissory notes, credit curve yields for bonds, and synthetic curves based on discount margin spreads.

Maturities of lease liabilities as of December 31, 2021 were as follows:


(in thousands)	December 31, 2021
2022	$	327
2023	300
2024	269
2025	257
2026	264
Thereafter	528
Total lease payments	1945
Less: imputed interest	(179)
Less: lease liabilities, current	(280)
Lease liabilities, non-current	$	1,486

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments In connection with the closing of the Business Combination, the Company entered into the Investor Rights Agreement on June 25, 2021 (the “Investor Rights Agreement”), pursuant to which the holders of Registrable Securities (as defined therein) became entitled to, among other things, customary registration rights, including demand, piggy-back and shelf registration rights. The Investor Rights Agreement also provides that the Company will pay certain expenses relating to such registrations and indemnify the registration rights holders against (or make contributions in respect of) certain liabilities which may arise under the Securities Act. On July 15, 2021, the Company registered the Registrable Securities for resale pursuant to a registration statement on Form S-1, as amended (File No. 333-257931) that became effective on July 30, 2021. In May 2018, the Company executed operating and maintenance agreements for certain services, to facilitate the development and thus bring Origin 1 to the condition necessary for its intended use, commencing in different periods between July 2018 and September 2019, and all generally for five-year periods. The agreements are generally automatically extended for one-year periods thereafter. The agreements include annual fixed payments subject to escalation clauses at the beginning of each calendar year, as defined in the agreement. The minimum fixed payments are $0.4 million (in Canadian dollars) per year over the fixed term. Certain of the agreements include quantities that are based on volumes, as defined in the applicable agreements. The Company is also responsible for applicable taxes under these agreements. During the year ended December 31, 2021 and 2020, the total amount capitalized into Property, Plant and Equipment, Net under the agreement was $0.1 million. In May 2019, the Company also concurrently executed a take-or-pay steam supply agreement commencing by October 1, 2019, through December 31, 2022, whereby the Company will receive up to 25% for the first year and 50% thereafter of the steam generated, up to 140,000 MMBTUs per year. The price paid for the steam is based on a fixed amount plus the supplier’s cost of natural gas, as defined in the agreement. During the year ended December 31, 2021 and 2020, the total amount capitalized into Property, Plant and Equipment, Net under the agreement was $0.1 million. In May 2018, the Company entered into a joint development agreement (the “JDA”) with a legacy stockholder to evaluate alternative uses for one of the Company’s products. The term of the JDA is the later of (i) 3 years from the JDA effective date and (ii) the final expected development program completion date as specified in the JDA. There were no expenses under this agreement for the year ended December 31, 2021 or 2020. Patent licenses In July 2017, the Company entered into a patent license agreement for $0.1 million, which expires upon expiration of the last patent in December 2025. Under this agreement, the Company will pay minimum royalty payments of $5,000 per year and, if the Company develops and sells certain products based on the patent, up to a maximum of $25,000 per year. Certain products that Origin is currently developing and anticipates selling are expected to utilize these patents. In December 2016, the Company entered into a patent license agreement for $0.5 million, which expires upon expiration of the patent. Under this agreement, if the Company develops and sells specific products based on the patent, the Company would pay a royalty up to a cumulative $0.5 million from Origin 1, whereby no further payments will be due for any production at Origin 1. If production of those products occurs at subsequent facilities, the Company will pay an upfront license fee royalty and a variable royalty based on production at that subsequent facility, capped at an aggregate $10 million per facility. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the year ended December 31, 2021 or 2020. In November 2016, the Company entered into a patent license agreement for $35.0 thousand, which expires upon expiration of the patent. Under this agreement, if the Company produces products based on the patent, the Company will pay an annual royalty upon commencement of operations on Origin 1 of $25.0 thousand up to a cumulative $1.0 million. The pipeline of Company products and sales are not currently expected to be subject to this patent. No payments were made during the year ended December 31, 2021 or 2020. In August 2015, the Company entered into a patent license agreement, which expires upon expiration of the patent. Under this agreement, if the Company develops and sells specific products based on the patent, the Company would pay a royalty up to $2.0 million per year and $10.0 million in the aggregate. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the year ended December 31, 2021 or 2020. In June 2011, the Company entered into a nonexclusive patents license agreement, which expires upon expiration of the last patent to expire. Under this agreement, the Company pays a royalty of $5.0 thousand annually and if the Company develops and sells specific products based on the patent, 0.4% of net sales. The pipeline of Company products and sales are not currently expected to be subject to this patent. Contingencies At times there may be claims and legal proceedings generally incidental to the normal course of business that are pending or threatened against the Company. Although the Company cannot predict the outcome of these matters when they arise, in the opinion of management, any liability arising from them will not have a material adverse effect on the consolidated financial position, results of operations, or liquidity of the Company. At December 31, 2021 and December 31, 2020, there were no claims or legal proceedings.

Basic and Diluted Net Income (Loss) Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Basic and Diluted Net Income (Loss) Per Share

The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common stockholders, which excludes Sponsor Vesting Shares which are legally outstanding, but subject to return to the Company. Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of common shares outstanding during the period, plus the dilutive effect of the stock options, RSU awards and convertible preferred stock warrants, as applicable pursuant to the treasury stock method, and the convertible notes, as applicable pursuant to the if-converted method. The following table sets forth the computation of basic and diluted net income (loss) per share:


(In thousands, except for share and per share amounts)	Year Ended December 31,
		2021		2020
Numerator:
Net income (loss) attributable to common stockholders—Basic		$	42,090	$	(30,302)

Net income (loss) attributable to common stockholders—Diluted		$	42,090	$	(30,302)
Denominator:
Weighted-average common shares outstanding—Basic (1)		101,221,781		62,544,933
Stock options		4,954,919		—
RSU awards		61,054		—
Weighted-average common shares outstanding—Diluted (1)		106,237,754		62,544,933
Net income (loss per share)—Basic		$	0.42	$	(0.48)
Net income (loss per share)—Diluted		$	0.40	$	(0.48)

__________________

(1)Excludes weighted-average Sponsor Vesting Shares subject to return of 2,342,466 and — shares for the year ended December 31, 2021 and December 31, 2020, respectively.

Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. As of December 31, 2021, options for 1,481,531 shares of common stock, performance awards for 2,137,500 shares of common stock, earnout shares for 25,000,000 shares of common stock, and Sponsor Vesting Shares for 4,500,000 shares of common stock were excluded from the table below because they are subject to market or performance conditions that were not achieved as of December 31, 2021.

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net income (loss) per share attributable to common stockholders for the periods presented because including them would have been antidilutive:


	Year Ended December 31,
		2021	2020
Options to purchase common stock		—	8,222,710
Warrants to purchase common stock		35,476,667	—
Warrants to purchase redeemable convertible preferred stock, as-converted		2,678,320	5,554,470

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). Pursuant to the Merger Agreement, the merger between Merger Sub and Legacy Origin was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Artius was treated as the “acquired” company and Legacy Origin is treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Legacy Origin issuing stock for the net assets of Artius, accompanied by a recapitalization. The net assets of Artius are stated at historical cost, with no goodwill or other intangible assets recorded. Legacy Origin was determined to be the accounting acquirer based on the following predominant factors: •the Company’s Board of Directors (the “Board”) and management are primarily composed of individuals associated with Legacy Origin; •Legacy Origin’s senior management comprise the senior management roles of the Company and are responsible for the day-to-day operations; •the Company assume the “doing business as” name of the Legacy Origin; and •The intended strategy and operations of the Company continue Legacy Origin’s current strategy and operations as a carbon negative materials company with a mission to enable the world’s transition to sustainable materials. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Legacy Origin. The shares and corresponding capital amounts and losses per share, prior to the Business Combination, have been retroactively restated based on shares reflecting the Exchange Ratio (as defined below) established in the Business Combination.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to the valuation of common stock and valuation of convertible preferred stock warrants prior to the Business Combination, valuation of the earnout liability, valuation of assumed common stock warrants liability, carrying amount and useful lives of property and equipment and intangible assets, impairment assessments, marketable securities, stock-based compensation expense, probabilities of achievement of performance conditions on performance stock awards, among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC and include the accounts of the Company and its wholly-owned subsidiaries, Origin Materials Canada Holding Limited, Origin Materials Canada Polyesters Limited, Origin Material Canada Pioneer Limited, Origin Materials Canada Research Limited, and Micromidas, Inc. (now known as Origin Materials Operating, Inc.). All intercompany accounts and transactions have been eliminated in consolidation.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and marketable securities accounts with a financial institution where, at times, deposits exceed federal insurance limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts. Restricted cash consists of cash held in a control account as collateral for the Company’s credit card services, escrow services, and standby letter of credit. These restricted cash balances have been excluded from cash and cash equivalents balance and are included within other current assets in the Consolidated Balance Sheets based on the respective maturity dates.
Marketable Securities	Marketable Securities The Company’s investment policy is consistent with the definition of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component on the consolidated statements of comprehensive income until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses, as required by new accounting pronouncement, Accounting Standards Update No. 2016-13 (“ASU 2016-13”), discussed in further detail below. Expected credit losses on securities are recognized in other income (expense), net on the consolidated statements of operations and comprehensive loss, and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive loss in the consolidated statement of redeemable convertible preferred stock and stockholders' equity. For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Interest on securities classified as available for sale is included as a component of interest income within other income (expense). The nature of these financial instruments include instruments for which quoted prices are available but traded less frequently, instruments whose fair value has been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data, and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 2 financial instruments include agency mortgage-backed securities, corporate fixed income securities infrequently traded, and other securities, which primarily consist of sovereign debt, U.S. government agency securities, loans, and state and municipal securities.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluated the stockholder convertible notes payable in accordance with ASC 815, Derivatives and Hedging and determined that the embedded components of these contracts qualify as a derivative to be separately accounted for as a liability. The Company records the fair value of the embedded components in accordance with ASC 815, Derivatives and Hedging. The fair value of the derivatives was calculated using a model that estimated the value that would be paid to transfer the liability in an orderly transaction between market participants at the measurement date. The fair value of the derivative liabilities is revalued on each balance sheet date with a corresponding gain or loss recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss). The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the consolidated balance sheets. Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized in the change in fair value of derivatives within other (income) expense. While the contract or notional amount is often used to express the volume of foreign currency derivative contracts, the amounts potentially subject to credit risk are generally limited to the amounts, if any, by which the counterparties’ obligations under the agreements exceed the obligations of the Company to the counterparties.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3). Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market. The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. The fair value of debt approximates its carrying value based on prevailing market rates. The fair values of the assumed common stock warrants which are publicly traded are level 1 inputs. The fair value of the assumed common stock warrants which are not publicly traded, cash equivalents, marketable securities, and foreign currency derivative contracts are level 2 inputs as the Company uses quoted market prices or alternative pricing sources and models utilizing observable market inputs. The earnout liability, derivative liability and redeemable convertible preferred stock warrant liability were estimated using Level 3 inputs.
Other Receivables	Other Receivables Other receivables consist of amounts due from foreign governmental entities related to the Canadian harmonized sales tax (HST) and goods and services tax (GST) for goods and services transacted in Canada, and amounts due from cash collateral held by others for foreign currency derivative contracts.
AgriScience Grant	AgriScience Grant In January 2019, the Company entered into an agreement in which it will participate in the AgriScience Program Cluster Component grant through the Canadian Agricultural Partnership, whereby the Company will receive reimbursements for eligible expenditures up to approximately $2.7 million (in Canadian dollars) through March 2022. Grants are received through reimbursements from the Canadian government and recognized, upon completion of scope of services on a quarterly basis. Grants are recognized as a reduction of property, plant, and equipment or expense based on the nature of the cost the grant is reimbursing.
Property, Plant, and Equipment	Property, Plant, and Equipment Property, plant, and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. Existing useful lives range from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of their estimated useful lives or the lease term. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to operations. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts. Costs incurred to acquire, construct or install property, plant, and equipment during the construction stage of a capital project and costs capitalized in conjunction with major improvements that have not yet been placed in service are recorded as construction in progress, and accordingly are not currently being depreciated. The Company capitalizes interest cost incurred on funds used to construct property, plant and equipment.
Intangible Assets	Intangible Assets Intangible assets are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the respective assets, ranging from 7 to 15 years. The cost of servicing the Company’s patents is expensed as incurred. Upon retirement or sale, the cost of intangible assets is disposed of and the related accumulated amortization is removed from the accounts.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its long-lived assets, including property, equipment, software and intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If indicators of impairment exist, management identifies the asset group which includes the potentially impaired long-lived asset, at the lowest level at which there are separate, identifiable cash flows. If the total of the expected undiscounted future net cash flows for the asset group is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset.
Government Loans	Government Loans Government loans are classified as a noncurrent liability and recorded at amortized cost. Forgiveness of the balances due is recorded through earnings and occurs when there is confirmation from the governmental authority that the Company has complied with the conditions for forgiveness attached to the loan.
Debt Issuance Costs	Debt Issuance Costs The costs incurred in connection with the issuance of debt obligations, principally financing and legal costs, are capitalized. These costs are accreted over the term of the debt using the interest method.
Redeemable Convertible Preferred Stock Warrants Liability	Redeemable Convertible Preferred Stock Warrants Liability Free-standing warrants issued by Legacy Origin for the purchase of shares of its convertible preferred stock were classified as liabilities on the accompanying balance sheets at fair value using an Option-Pricing Model (“OPM”). Prior to the Business Combination, the liability recorded was adjusted for changes in the fair value at each reporting date and recorded as interest expense in the accompanying Consolidated Statements of Operations and Comprehensive Income (Loss). As a result of the Business Combination, the Legacy Origin warrants each converted into a warrant to purchase shares of the Company’s Common Stock converted at the Exchange Ratio. The fair value of the warrants upon consummation of the Business Combination (see Note 4), as adjusted based on the price of the underlying Common Stock, was reclassified to additional paid-in capital.
Assumed Common Stock Warrants Liability	Assumed Common Stock Warrants Liability The Company assumed 24,150,000 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Assumed Common Stock Warrants”) upon the Business Combination, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A Common Stock at an exercise price of at $11.50 per share. As of December 31, 2021, 24,150,000 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants. The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”), and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the Assumed Common Stock Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves 50% or more of our Class A stockholders. Because not all of the voting stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Assumed Common Stock Warrants do not meet the conditions to be classified in equity. Since the Assumed Common Stock Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in the change in fair value of Assumed Common Stock Warrant liabilities within the Consolidated Statements of Operations and Comprehensive Income (Loss) at each reporting date. The Public Warrants were publicly traded and thus had an observable market price to estimate fair value, and the Private Placement Warrants were effectively valued similar to the Public Warrants, as described in Note 6.
Earnout Liability	Earnout Liability The Company has recorded an earnout liability related to future contingent equity shares related to the Business Combination (Note 13). The Company recorded these instruments as liabilities on the Consolidated Balance Sheet at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date.
Leases	Leases We have operating leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC 842, Leases. We recognize a right-of-use asset and lease liability for operating leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain.
Research and Development Cost	Research and Development Cost Costs related to research and development are expensed as incurred.
Stock-Based Compensation	Stock-Based Compensation The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including: •Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term. •Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor. •Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future. •Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate. •Risk-free interest rate – The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with the same or substantially equivalent remaining term.
Income Taxes	Income Taxes Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters as a component of income tax expense.
Functional Currency Translation	Functional Currency Translation The functional currency of the Company’s wholly-owned subsidiaries is the Canadian dollar, whereby their assets and liabilities are translated at period-end exchange rates except for nonmonetary capital transactions and balances, which are translated at historical rates. All income and expense amounts of the Company are translated at average exchange rates for the respective period. Translation gains and losses are not included in determining net loss but are accumulated in a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the determination of net loss in the period in which they occur. These amounts are included in other income, net, of the Consolidated Statements of Operations and Comprehensive Income (Loss).
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company’s comprehensive income or loss consists of net income or loss and other comprehensive income (loss). Foreign currency translation gains or losses and unrealized gains or losses on available-for-sale marketable debt securities are included in the Company’s other comprehensive income (loss).
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net income (loss) per share calculation, the convertible preferred stock, common stock options, RSU awards, performance stock awards, convertible preferred stock warrants, common stock warrants, convertible notes, earnout shares, and Sponsor Vesting Shares (as defined below) are considered to be potentially dilutive securities. Basic and diluted net income (loss) per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. All series of the Company’s convertible preferred stock are considered to be participating securities because, in addition to cumulative dividends, all holders are entitled to receive a non-cumulative dividend on a pari passu basis in the event that a dividend is paid on the common stock. The two-class method requires income or loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income or loss for the period had been distributed. The holders of the convertible preferred stock do not have a contractual obligation to share in the Company’s losses. Accordingly, the Company’s net income (loss) is attributed entirely to common stockholders. For the periods presented that the Company has reported a net loss, diluted net loss per common share is the same as basic net loss per common share for those periods.
Reclassifications	Reclassifications Certain amounts in prior periods have been reclassified to conform with the report classifications of the year ended December 31, 2021, noting the Company has reflected the reverse recapitalization pursuant to the Business Combination for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity.
Segment Reporting	Segment Reporting The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company has determined that its Co-Chief Executive Officers are the CODM. To date, the Company’s CODM has made such decisions and assessed performance at the Company level.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740), to simplify the accounting for income taxes. The new guidance changes various subtopics of accounting for income taxes including, but not limited to, accounting for “hybrid” tax regimes, tax basis step-up in goodwill obtained in a transaction that is not a business combination, intraperiod tax allocation exception to incremental approach, ownership changes in investments, interim-period accounting for enacted changes in tax law, and year-to-date loss limitation in interim-period tax accounting. The Company early adopted the new standard as of January 1, 2021. The adoption of the standard had no material impact on the Company’s financial results. In February 2016, the FASB issued an ASU 2016-02, Leases (Topic 842), that amends the accounting guidance on leases. The standard establishes a right-of-use (ROU) model that requires a lessee to record an ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The FASB also subsequently issued amendments to the standard, including providing an additional and optional transition method to adopt the new standard, described below, as well as certain practical expedients related to land easements and lessor accounting. We adopted this accounting standard effective January 1, 2021, using the optional transition method with no restatement of comparative periods. Therefore, the comparative information has not been adjusted and continues to be reported under ASC Topic 840. Our adoption of the new standard did not result in a cumulative effect adjustment to retained earnings. The adoption had a material effect on the Company’s consolidated financial statements. The most significant effects relate to (1) the recognition of new right-of-use assets and lease liabilities on our consolidated balance sheet for our building leases; and (2) providing significant new disclosures about our leasing activities. The Company also elected the package of practical expedients to leases that commenced before the effective date whereby we elected to not reassess the following: i.whether any expired or existing contracts contain leases; ii.the lease classification for any expired or existing leases; and iii.initial direct costs for any existing leases. Upon adoption of ASU 2016-02, we did not record right-of-use assets or lease liabilities for leases with an initial term of 12 months or less. Payments on those leases will be recognized on a straight-line basis over the lease term. We elected to combine lease and non-lease components on new or modified leases after adoption. Upon adoption as of January 1, 2021, we recorded $1.8 million in right-of-use assets and operating lease liabilities. In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, and includes the Company's accounts receivable, certain financial instruments and contract assets. ASU 2016-13 results in more timely recognition of credit losses. Effective for our annual period as of January 1, 2021, the Company adopted the provisions and expanded disclosure requirements described in ASU 2016-13. The adoption of ASU 2016-13 was not material to the consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance. The FASB issued this update to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The main provisions of this update require the following annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy: i.Information about the nature of the transactions and the related accounting policy used to account for the transactions ii.The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item iii.Significant terms and conditions of the transactions, including commitments and contingencies. The Company anticipates this will impact disclosures relating to their AgriScience Grant, PPP Loan, and Canadian Government Research and Development Program Liability. The amendments in this update are effective for the Company in the annual period beginning after December 15, 2021. Early application of the amendments is permitted. The Company has elected to adopt on January 1, 2022. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) Recognition of an acquired contract liability; and (2) Payment terms and their effect on subsequent revenue recognized by the acquirer. Specifically, the update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers. The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in an interim period. The Company does not believe the adoption of this standard will have a material effect on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The guidance is effective for fiscal years beginning on or after December 15, 2021, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company does not believe the adoption of this standard will have a material effect on its consolidated financial statements. In March 2020, the Financial Accounting Standards Board issued ASU No. 2020-04, Reference Rate Reform, which provides temporary optional guidance to companies impacted by the transition away from the London Interbank Offered Rate (“LIBOR”). The guidance provides certain expedients and exceptions to applying U.S. GAAP in order to lessen the potential accounting burden when contracts, hedging relationships, and other transactions that reference LIBOR as a benchmark rate are modified. The provisions of the new standard may be adopted as of the beginning of the reporting period when the election is made until December 31, 2022. The Company does not believe the adoption of this standard will have a material effect on its consolidated financial statements. The Company has elected to adopt on January 1, 2022.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Schedule of Cash, Cash Equivalents, and Restricted Cash

Cash, cash equivalents, and restricted cash consisted of the following (in thousands):


	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	46,637	$	1,309
Restricted cash	$	490	$	565
Total cash, cash equivalents, and restricted cash	$	47,127	$	1,874

Schedule of Estimated Useful Lives of Assets

The estimated useful lives of assets are as follows:


Computer Equipment			3 years
Office Furniture			5 years
Machinery and Equipment			5 years
Leasehold Improvements			1-5 years

Business Combination (Tables)

12 Months Ended

Dec. 31, 2021

Business Combination and Asset Acquisition [Abstract]

Summary of Element of the Net Proceeds of Business Combination

The following table summarizes the elements of the net proceeds from the Business Combination at the date of acquisition (in thousands):


Cash—Trust Account (net of redemptions of $439 million)	$	260,448
Cash	60
Cash—PIPE & Backstop Financing	243,000
Non-cash net assets assumed from Artius	40
Less: Fair value of assumed common stock warrants	(83,370)
Less: Underwriting fees and other issuance costs paid prior to the date of acquisition	(34,773)
Additional Paid-in-Capital from Business Combination, net of issuance costs paid	$	385,405
Less: Non-cash net assets assumed from Artius	(40)
Add: Non-cash fair value of assumed common stock warrants	83,370
Add: Other issuance costs included in accounts payable and accrued liabilities	761
Less: Accrued liabilities extinguished through proceeds from Business Combination	(1,966)
Cash proceeds from the Business Combination	$	467,530

Summary of Number Shares of Common Stock Outstanding

The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination:


Artius shares outstanding prior to the Business Combination, including 4,500,000 Sponsor Vesting Shares			90,562,500
Less: redemption of Artius shares			(43,880,956)
Shares issued pursuant to the PIPE and Backstop Financing			24,300,001
Business Combination and PIPE Financing shares, including 4,500,000 Sponsor Vesting Shares			70,981,545
Conversion of Legacy Origin Series A preferred stock for common stock			33,783,099
Conversion of Legacy Origin Series B preferred stock for common stock			19,755,784
Conversion of Legacy Origin Series C preferred stock for common stock			6,286,349
Conversion of Legacy Origin convertible notes for common stock			2,049,212
Conversion of Legacy Origin common stock for common stock			2,838,041
Issuance of common stock upon exercise of warrants			5,554,440
Total shares of the Company common stock outstanding immediately following the Business Combination			141,248,470

Fair Value Measurement (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Summary Of Assets And Liabilities Measured At Fair Value

The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows:


	Fair Value as of December 31, 2021
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash, cash equivalents and restricted cash	$	47,127	$	—	$	—	$	47,127
Marketable securities	—		397,458		—		397,458
Derivative asset	—		202		—		202
Total fair value	$	47,127	$	397,660	$	—	$	444,787
Liabilities:
Assumed common stock warrants (Public)	$	35,983	$	—	$	—	$	35,983
Assumed common stock warrants (Private Placement)	—		16,877		—		16,877
Earnout liability	—		—		127,757		127,757
Derivative liability	—		103		—		103
Total fair value	$	35,983	$	16,980	$	127,757	$	180,720


	Fair Value as of December 31, 2020
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash, cash equivalents and restricted cash	$	1,874	$	—	$	—	$	1,874
Total fair value	$	1,874	$	—	$	—	$	1,874
Liabilities:
Redeemable convertible preferred stock warrants liability	$	—	$	—	$	19,233	$	19,233
Derivative liability	—		—		1,239		1,239
	$	—	$	—	$	20,472	$	20,472

Schedule of Marketable Securities


	As of December 31, 2021
(in thousands)
Investments Classified as Marketable Securities	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Corporate bonds	$	274,939	$	100	$	(1,725)	$	273,314
Asset-backed securities	96,713		190		(199)		96,704
U.S. government and agency securities	20,235		—		(64)		20,171
Foreign government and agency securities	3,262		—		(19)		3,243
Municipal/provincial bonds and other	4,000		5		—		4,005
Total	$	399,149	$	295	$	(2,007)	$	397,437
Pending purchases and sales	21		—		—		21
Total marketable securities	$	399,170	$	295	$	(2,007)	$	397,458

Schedule of Marketable Security Contractual Maturities

The contractual maturities of the investments classified as marketable securities are as follows (in millions):



(in thousands)	Mature within one year		Mature after one year through two years		Mature over two years		Fair Value
Corporate bonds	$	92,559	$	134,199	$	46,556	$	273,314
Asset-backed securities	—		2,000		94,704		96,704
U.S. government and agency securities	—		7,995		12,176		20,171
Foreign government and agency securities	2,877		—		366		3,243
Municipal/provincial bonds and other	2,002		2,003		—		4,005
Total	$	97,438	$	146,197	$	153,802	$	397,437
Pending purchases and sales							21
Total marketable securities	$	97,438	$	146,197	$	153,802	$	397,458

Summary of Key Assumptions for Determining Fair Value of Redeemable Convertible Preferred Stock Warrants

A summary of key assumptions in the BSM for determining the fair value of redeemable convertible preferred stock warrants include:


	December 31, 2020
Expected life (years)	3.00
Risk-free interest rate	0.17	%
Expected volatility	70.00	%
Dividend yield	0	%

Summary of Fair Value of Redeemable Convertible Preferred Stock Warrants Liability and Derivative Liability

recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs:


Redeemable Convertible Preferred Stock Warrant	Years Ended December 31,
(in thousands)	2021		2020
Beginning warrant liability balance	$	19,233	$	735
Change in fair value of warrants liability	35,034		18,498
Reclassification to APIC upon recapitalization	(54,267)		—
Ending warrant liability balance	$	—	$	19,233

Embedded Derivative - Stockholder Convertible Notes Payable	Years Ended December 31,
(in thousands)	2021		2020
Beginning derivative liabilities balance	$	1,238	$	150
Change in fair value	(1,238)		1,088
Ending derivative liabilities balance	$	—	$	1,238

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of Property Plant and Equipment

Property, plant, and equipment consisted of the following:


(in thousands)	December 31, 2021		December 31, 2020
Land	$	912	$	39
Pilot plant	5,517		5,237
Lab equipment	2,227		1,958
Machinery and equipment	655		655
Computer and other equipment	388		295
Construction in process	55,026		43,962
	64,725		52,146
Less accumulated depreciation and amortization	(7,540)		(7,042)
Total property, plant, and equipment, net	$	57,185	$	45,104

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Intangible assets consisted of the following:


(in thousands)	December 31, 2021		December 31, 2020
Patents	$	432	$	430
Less accumulated amortization	(217)		(172)
	$	215	$	258

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2021

Stockholders' Equity Note [Abstract]

Summary of Stock Option Activity

The following tables summarize the activity under the Stock Plans:


	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (in years)
Balance at December 31, 2019	2,205,015	$	0.36	3.89
Granted	6,296,302	$	0.14
Exercised	(2,912)	$	0.37
Forfeited / canceled	(275,695)	$	0.43
Balance at December 31, 2020	8,222,710	$	0.19	8.30
Granted	—
Exercised	(171,118)	0.42
Forfeited / canceled	(158,735)	0.14
Balance as of December 31, 2021	7,892,857	$	0.19	7.31
Vested and expected to vest at December 31, 2021	7,872,978

Schedule of RSU and Performance Award Activity

RSU award and performance award activity for the year ended December 31, 2021 is as follows:


	Restricted Stock Outstanding
	Outstanding	Weighted-average grant date fair value
Balance at December 31, 2020	—
Granted - RSU awards	769,505	7.34
Granted - performance awards	2,137,500	7.35
Balance at December 31, 2021	2,907,005	7.35
Expected to vest	769,505

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax

Income (loss) before provision for income taxes consisted of the following:


(in thousands)	December 31, 2021		December 31, 2020
United States	$	43,645	$	(29,162)
International	(1,554)		(1,141)
Income (loss) before provision for income taxes	$	42,091	$	(30,303)

Schedule of Federal and State Income Tax Provision

The federal and state income tax expense is summarized as follows:


(in thousands)	December 31, 2021		December 31, 2020
Current
Federal	$	—	$	—
State	3		2
International	—		—
Total current tax expense	3		2
Deferred
Federal	—		—
State	—		—
International	—		—
Total deferred tax expense	—		—

Total tax expense	$	3	$	2

Schedule of Deferred Tax Assets and Liabilities

The tax effects of significant items comprising the Company's deferred taxes are as follows:


(in thousands)	December 31, 2021		December 31, 2020
Deferred tax assets
Net operating loss carryforwards	$	24,899	$	18,400
Available for Sale Securities	390		—
Lease liability	341		—
Other	230		149
Fixed assets and intangibles	89		114
Total deferred tax assets	25,949		18,663

Deferred tax liabilities
ROU asset	(344)		—
Total deferred tax liabilities	(344)		—

Valuation allowance	(25,605)		(18,663)
Net deferred taxes	$	—	$	—

Schedule of Effective Tax Rate

The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows:


	December 31, 2021		December 31, 2020
Statutory rate	21.0	%	21.0	%
State tax	(1.3)		(0.1)
Warrants, BCF, and other equity items	(33.3)		(13.1)
Valuation allowance	15.6		(6.4)
Other	(0.2)		(0.1)
Foreign rate differential	(0.2)		0.2
Stock-based compensation	(1.6)		(1.5)
Total	—	%	—	%

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Components of Lease Cost and Other Information

The components of lease cost were as follows:


(in thousands)	December 31, 2021




Operating lease cost	$	324
Variable lease cost	68
Total lease cost	$	392

Other information related to leases is as follows:


(in thousands)	December 31, 2021

Operating lease ROU asset (included within Lease right-of-use asset)	$	1,782

Weighted average remaining lease term (in years):

Operating leases	7.44
Weighted average discount rate:

Operating leases	2.8		%


(in thousands)	December 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	271


ROU assets obtained in exchange for operating lease liabilities	$	2,062

Operating Lease Maturity

Maturities of lease liabilities as of December 31, 2021 were as follows:


(in thousands)	December 31, 2021
2022	$	327
2023	300
2024	269
2025	257
2026	264
Thereafter	528
Total lease payments	1945
Less: imputed interest	(179)
Less: lease liabilities, current	(280)
Lease liabilities, non-current	$	1,486

Basic and Diluted Net Income (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Summary of basic and diluted loss per ordinary share

RSU awards and convertible preferred stock warrants, as applicable pursuant to the treasury stock method, and the convertible notes, as applicable pursuant to the if-converted method. The following table sets forth the computation of basic and diluted net income (loss) per share:


(In thousands, except for share and per share amounts)	Year Ended December 31,
		2021		2020
Numerator:
Net income (loss) attributable to common stockholders—Basic		$	42,090	$	(30,302)

Net income (loss) attributable to common stockholders—Diluted		$	42,090	$	(30,302)
Denominator:
Weighted-average common shares outstanding—Basic (1)		101,221,781		62,544,933
Stock options		4,954,919		—
RSU awards		61,054		—
Weighted-average common shares outstanding—Diluted (1)		106,237,754		62,544,933
Net income (loss per share)—Basic		$	0.42	$	(0.48)
Net income (loss per share)—Diluted		$	0.40	$	(0.48)

__________________

(1)Excludes weighted-average Sponsor Vesting Shares subject to return of 2,342,466 and — shares for the year ended December 31, 2021 and December 31, 2020, respectively.

Summary of antidilutive securities excluded from computation of earnings per share


	Year Ended December 31,
		2021	2020
Options to purchase common stock		—	8,222,710
Warrants to purchase common stock		35,476,667	—
Warrants to purchase redeemable convertible preferred stock, as-converted		2,678,320	5,554,470

Risks and Liquidity - Narrative (Detail) $ in Millions	12 Months Ended
Risks and Liquidity - Narrative (Detail) $ in Millions	Dec. 31, 2021 USD ($)
Risks And Liquidity [Abstract]
Proceeds for business combination	$ 444.6

Summary of Significant Accounting Policies - Narrative (Detail) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2019 CAD ($)	Dec. 31, 2021 USD ($) plan Segment $ / shares shares	Dec. 31, 2020 USD ($)	Oct. 31, 2019 USD ($)
Significant Accounting Policies [Line Items]
Escrow deposit fair value				$ 1,300,000
Escrow deposit		$ 300,000	$ 300,000
Grants received		0	200,000
Impairment of long lived assets		0	0
Accretion expense for debt issuance cost		$ 2,200,000	100,000
Exercise price (in dollars per share) \| $ / shares		$ 11.50
Outstanding warrants (in shares) \| shares		35,476,667
Percent of occurrence of a tender offer or exchange of our stockholders		50.00%
Number of equity incentive plans (in plans) \| plan		3
Number of operating segments (in segments) \| Segment		1
Total assets		$ 510,417,000	47,429,000
Foreign currency contract
Significant Accounting Policies [Line Items]
Derivative, notional amount		$ 63,700,000	0
Public Warrants
Significant Accounting Policies [Line Items]
Number of warrants assumed (in shares) \| shares		24,150,000
Outstanding warrants (in shares) \| shares		24,150,000
Private Placement Warrants
Significant Accounting Policies [Line Items]
Number of warrants assumed (in shares) \| shares		11,326,667
Outstanding warrants (in shares) \| shares		11,326,667
Maximum
Significant Accounting Policies [Line Items]
Reimbursement for eligible expenditure	$ 2.7
Estimated useful lives		5 years
Intangible assets, estimated useful lives		15 years
Minimum
Significant Accounting Policies [Line Items]
Estimated useful lives		3 years
Intangible assets, estimated useful lives		7 years
Outside United States
Significant Accounting Policies [Line Items]
Total assets		$ 60,600,000	45,400,000
Standby Letters of Credit
Significant Accounting Policies [Line Items]
Letter of credit		$ 200,000	$ 200,000

Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 46,637	$ 1,309
Restricted cash	490	565
Total cash, cash equivalents, and restricted cash	$ 47,127	$ 1,874	$ 3,612

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2021
Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Computer Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office Furniture
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold Improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year
Leasehold Improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years

Business Combination - Narrative (Detail) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 25, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Business Acquisition [Line Items]
Business combination, net of issuance costs paid	$ 467,530	$ 467,530	$ 0
Conversion ratio	2.11
Business combination, acquisition related costs		36,700
Proceeds from issuance of common stock		$ 74	$ 1
Common stock, shares issued (in shares) \| shares		141,301,569	70,266,925
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001	$ 0.0001
Artius
Business Acquisition [Line Items]
Business combination, net of issuance costs paid	$ 467,500
Number of vesting shares (in shares) \| shares		4,500,000
PIPE investors
Business Acquisition [Line Items]
Issue of common stocks, Initial public offering (in shares) \| shares		20,000,000
Proceeds from issuance of common stock		$ 200,000
Subscription shares
Business Acquisition [Line Items]
Common stock, shares issued (in shares) \| shares		4,300,001
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001
Share price (in dollars per share) \| $ / shares		$ 10.00

Business Combination - Summary of Element of the Net Proceeds of Business Combination (Detail) - USD ($) $ in Thousands		12 Months Ended
	Jun. 25, 2021	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Business combination, net of issuance costs paid	$ 467,530	$ 467,530	$ 0
Artius
Business Acquisition [Line Items]
Cash—Trust Account (net of redemptions of $439 million)	260,448
Assets Held-in-trust	439,000
Cash	60
Cash—PIPE & Backstop Financing	243,000
Business combination, non cash net Assets assumed from Artius	(40)
Less: Fair value of assumed common stock warrants	(83,370)
Less: Underwriting fees and other issuance costs paid prior to the date of acquisition	(34,773)
Additional Paid-in-Capital from Business Combination, net of issuance costs paid	385,405
Add: Non-cash fair value of assumed common stock warrants	83,370
Add: Other issuance costs included in accounts payable and accrued liabilities	761
Less: Accrued liabilities extinguished through proceeds from Business Combination	(1,966)
Business combination, net of issuance costs paid	$ 467,500

Business Combination - Summary of Number Shares of Common Stock Outstanding (Detail) - Artius	12 Months Ended
	Dec. 31, 2021 shares
Business Acquisition [Line Items]
Artius shares outstanding prior to the Business Combination, excluding 4,500,000 Sponsor Vesting Shares (in shares)	90,562,500
Number of vesting shares (in shares)	4,500,000
Less: redemption of Artius shares (in shares)	(43,880,956)
Shares issued pursuant to the PIPE and Backstop Financing (in shares)	24,300,001
Business Combination and PIPE Financing shares, excluding 4,500,000 Sponsor Vesting Shares (in shares)	70,981,545
Conversion of Legacy Origin Series A preferred stock for common stock (in shares)	33,783,099
Conversion of Legacy Origin Series B preferred stock for common stock (in shares)	19,755,784
Conversion of Legacy Origin Series C preferred stock for common stock (in shares)	6,286,349
Conversion of Legacy Origin convertible notes for common stock (in shares)	2,049,212
Conversion of Legacy Origin common stock for common stock (in shares)	2,838,041
Issuance of common stock upon exercise of warrants (in shares)	5,554,440
Total shares of New Origin common stock outstanding immediately following the Business Combination (in shares)	141,248,470

Recent Accounting Pronouncements - Narrative (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Operating lease right-of-use asset	$ 1,782	$ 1,800	$ 0
Operating lease liability		$ 1,800

Fair Value Measurement - Summary of Assets And Liabilities Measured At Fair Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Assets:
Marketable securities	$ 397,458
Fair Value, Recurring
Assets:
Cash, cash equivalents and restricted cash	47,127	$ 1,874
Marketable securities	397,458
Derivative asset	202
Total fair value	444,787	1,874
Liabilities:
Earn-out liability	127,757
Derivative liability	103	1,239
Total fair value	180,720	20,472
Fair Value, Recurring \| Level 1
Assets:
Cash, cash equivalents and restricted cash	47,127	1,874
Marketable securities	0
Derivative asset	0
Total fair value	47,127	1,874
Liabilities:
Earn-out liability	0
Derivative liability	0	0
Total fair value	35,983	0
Fair Value, Recurring \| Level 2
Assets:
Cash, cash equivalents and restricted cash	0	0
Marketable securities	397,458
Derivative asset	202
Total fair value	397,660	0
Liabilities:
Earn-out liability	0
Derivative liability	103	0
Total fair value	16,980	0
Fair Value, Recurring \| Level 3
Assets:
Cash, cash equivalents and restricted cash	0	0
Marketable securities	0
Derivative asset	0
Total fair value	0	0
Liabilities:
Earn-out liability	127,757
Derivative liability	0	1,239
Total fair value	127,757	20,472
Assumed common stock warrants (Public) \| Fair Value, Recurring
Liabilities:
Warrants or rights outstanding	35,983
Assumed common stock warrants (Public) \| Fair Value, Recurring \| Level 1
Liabilities:
Warrants or rights outstanding	35,983
Assumed common stock warrants (Public) \| Fair Value, Recurring \| Level 2
Liabilities:
Warrants or rights outstanding	0
Assumed common stock warrants (Public) \| Fair Value, Recurring \| Level 3
Liabilities:
Warrants or rights outstanding	0
Assumed common stock warrants (Private Placement) \| Fair Value, Recurring
Liabilities:
Warrants or rights outstanding	16,877
Assumed common stock warrants (Private Placement) \| Fair Value, Recurring \| Level 1
Liabilities:
Warrants or rights outstanding	0
Assumed common stock warrants (Private Placement) \| Fair Value, Recurring \| Level 2
Liabilities:
Warrants or rights outstanding	16,877
Assumed common stock warrants (Private Placement) \| Fair Value, Recurring \| Level 3
Liabilities:
Warrants or rights outstanding	$ 0
Redeemable convertible preferred stock warrants liability \| Fair Value, Recurring
Liabilities:
Warrants or rights outstanding		19,233
Redeemable convertible preferred stock warrants liability \| Fair Value, Recurring \| Level 1
Liabilities:
Warrants or rights outstanding		0
Redeemable convertible preferred stock warrants liability \| Fair Value, Recurring \| Level 2
Liabilities:
Warrants or rights outstanding		0
Redeemable convertible preferred stock warrants liability \| Fair Value, Recurring \| Level 3
Liabilities:
Warrants or rights outstanding		$ 19,233

Fair Value Measurement - Summary of Marketable Securities (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 399,170
Unrealized Gains	295
Unrealized Losses	(2,007)
Fair Value	397,458
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	399,149
Unrealized Gains	295
Unrealized Losses	(2,007)
Fair Value	397,437
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	274,939
Unrealized Gains	100
Unrealized Losses	(1,725)
Fair Value	273,314
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	96,713
Unrealized Gains	190
Unrealized Losses	(199)
Fair Value	96,704
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	20,235
Unrealized Gains	0
Unrealized Losses	(64)
Fair Value	20,171
Foreign government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	3,262
Unrealized Gains	0
Unrealized Losses	(19)
Fair Value	3,243
Municipal/provincial bonds and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	4,000
Unrealized Gains	5
Unrealized Losses	0
Fair Value	4,005
Pending Purchases And Sales
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	21
Unrealized Gains	0
Unrealized Losses	0
Fair Value	$ 21

Fair Value Measurement - Marketable Security Contractual Maturities (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	$ 97,438
Mature after one year through two years	146,197
Mature over two years	153,802
Fair Value	397,458
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	92,559
Mature after one year through two years	134,199
Mature over two years	46,556
Fair Value	273,314
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	0
Mature after one year through two years	2,000
Mature over two years	94,704
Fair Value	96,704
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	0
Mature after one year through two years	7,995
Mature over two years	12,176
Fair Value	20,171
Foreign government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	2,877
Mature after one year through two years	0
Mature over two years	366
Fair Value	3,243
Municipal/provincial bonds and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	2,002
Mature after one year through two years	2,003
Mature over two years	0
Fair Value	4,005
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	97,438
Mature after one year through two years	146,197
Mature over two years	153,802
Fair Value	397,437
Pending Purchases And Sales
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value	$ 21

Fair Value Measurement - Narrative (Detail) - USD ($)	1 Months Ended		12 Months Ended
Fair Value Measurement - Narrative (Detail) - USD ($)	Nov. 30, 2019	Apr. 30, 2016	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Sales of marketable securities			$ 2,024,089,000	$ 0
Realized gain on marketable securities			200,000
Aggregate fair value of marketable securities in unrealized loss position			346,300,000
Aggregated fair value of marketable securities in continuous unrealized loss position for more than twelve months			0
Allowance for credit loss			$ 0
Exercise price (in dollars per share)			$ 11.50
Foreign currency contract
Class of Warrant or Right [Line Items]
Net gain on foreign currency derivative contracts			$ 100,000
Series A Preferred Stock Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)		122,400
Exercise price (in dollars per share)		$ 2.7233
Series A Preferred Stock Warrants \| 2012 Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)								1,000,000
Exercise price (in dollars per share)								$ 2.7233
Warrants exercise period								10 years
Warrants exercise period, extended	10 years
Series A Preferred Stock Warrants \| 2015 Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)							1,134,653
Exercise price (in dollars per share)							$ 2.7233
Warrants exercise period							10 years
Warrants exercise period, extended	10 years
Series B Preferred Stock Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)					35,412	331,927
Exercise price (in dollars per share)					$ 7.486	$ 7.486

Fair Value Measurement - Summary of Key Assumptions for Determining Fair Value of Redeemable Convertible Preferred Stock Warrants (Detail) - Redeemable Convertible Preferred Stock Warrant	Dec. 31, 2020 yr
Expected life (years)
Class of Warrant or Right [Line Items]
Fair value measurements inputs	3.00
Risk-free interest rate
Class of Warrant or Right [Line Items]
Fair value measurements inputs	0.0017
Expected volatility
Class of Warrant or Right [Line Items]
Fair value measurements inputs	0.7000
Dividend yield
Class of Warrant or Right [Line Items]
Fair value measurements inputs	0

Fair Value Measurement - Summary of Fair Value of Redeemable Convertible Preferred Stock Warrants Liability and Derivative Liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Redeemable Convertible Preferred Stock Warrant
Schedule Of Fair Value Of Redeemable Convertible Preferred Stock Warrants Liability And Derivative Liability [Roll Forward]
Beginning balance	$ 19,233	$ 735
Change in fair value	35,034	18,498
Reclassification to APIC upon recapitalization	(54,267)	0
Ending balance	0	19,233
Embedded Derivative - Stockholder Convertible Notes Payable
Schedule Of Fair Value Of Redeemable Convertible Preferred Stock Warrants Liability And Derivative Liability [Roll Forward]
Beginning balance	1,238	150
Change in fair value	(1,238)	1,088
Ending balance	$ 0	$ 1,238

Property, Plant and Equipment - Schedule of Property Plant and Equipment (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 64,725,000	$ 52,146,000
Less accumulated depreciation and amortization	(7,540,000)	(7,042,000)
Total property, plant, and equipment, net	0	0
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	912,000	39,000
Pilot plant
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	5,517,000	5,237,000
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,227,000	1,958,000
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	655,000	655,000
Computer and other equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	388,000	295,000
Construction in process
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 55,026,000	$ 43,962,000

Property, Plant and Equipment - Narrative (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0.5	$ 0.5
Capitalized interest cost	0.9	0.7
Cumulative translation adjustment	$ (0.1)	$ 0.9

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Patents	$ 432	$ 430
Less accumulated amortization	(217)	(172)
Intangible assets, net	$ 215	$ 258

Intangible Assets - Narrative (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible assets weighted average useful life	9 years 10 months 13 days
Amortization expense	$ 0.0	$ 0.0

Consortium Agreement - Narrative (Detail) - USD ($) $ in Millions		1 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2021	Dec. 31, 2020
Pledged Financial Instruments, Not Separately Reported, Securities, by Type of Agreement [Abstract]
Company received amount from agreement	$ 0.5	$ 0.5
Other income			$ 0.5	$ 0.6

PPP Loans - Narrative (Detail) - PPP Loan $ in Millions	1 Months Ended
PPP Loans - Narrative (Detail) - PPP Loan $ in Millions	Apr. 30, 2020 USD ($)
Debt Disclosure [Line Items]
Unsecured loan	$ 0.9
Loan facility term	2 years
Debt instrument, interest rate	1.00%

Related Party Transactions - Narrative (Detail) $ in Millions		1 Months Ended							12 Months Ended
	Dec. 31, 2016 USD ($)	Feb. 28, 2021 USD ($)	Jan. 31, 2021 USD ($)	Nov. 30, 2019 USD ($)	May 31, 2019 USD ($) installment	Aug. 31, 2018 USD ($)	Dec. 31, 2016 USD ($)	Nov. 30, 2016 USD ($)	Dec. 31, 2021 USD ($) agreement	Dec. 31, 2020 USD ($)
Debt Disclosure [Line Items]
Company received amount from agreement	$ 0.5						$ 0.5
Invested amount for research and development						$ 1.5
Number of offtake supply agreements (in agreements) \| agreement									4
Number of terminable offtake supply agreements (in agreements) \| agreement									2
Accrued interest									$ 10.9	$ 10.7
Liquidated damages										0.9
Offtake agreement exercise period									1 year
Offtake agreement purchase period									10 years
Other long-term debt								$ 5.0
Stockholder
Debt Disclosure [Line Items]
Line of credit facility, interest rate									0.38%
Debt instrument, increase, accrued interest										0.1
Other long-term debt									$ 5.1
Repayment period under prepayment agreement								5 years
Amount of repayment under prepayment agreement								$ 7.5
Repayment percentage of prepayment agreement amount								150.00%
Loan facility term									5 years
Unsecured Convertible Notes
Debt Disclosure [Line Items]
Debt conversion, converted instrument, amount		$ 50.0
Convertible notes		$ 10.0
Debt instrument, interest rate		8.00%
Promissory Note
Debt Disclosure [Line Items]
Debt instrument, interest rate					3.50%
Prepayment from stockholder								$ 5.0
Debt instrument, increase, accrued interest					$ 0.2
Number of installments (in installments) \| installment					3
Long-term debt, maturity, December 20, 2024									$ 2.2
Long-term debt, maturity, December 19, 2025									2.1
Long-term debt, maturity, December 18, 2026									2.1
Total debt outstanding									$ 5.2	5.2
Bridge Notes
Debt Disclosure [Line Items]
Line of credit facility, maximum borrowing capacity				$ 6.0
Line of credit facility, interest rate				10.00%
Conversion percentage of outstanding principal and unpaid accrued interest			70.00%	70.00%
Percentage of repay purchasers in cash amount during liquidation				200.00%
Bridge loan										$ 3.2
Debt conversion, converted instrument, amount			$ 50.0
SPAC transaction			$ 700.0
Bridge Notes \| Unsecured Convertible Notes
Debt Disclosure [Line Items]
Conversion percentage of outstanding principal and unpaid accrued interest		80.00%
Repayment premium as a percentage of principal		1

Other Liabilities, Long-term - Narrative (Detail) - USD ($) $ in Millions	1 Months Ended
	Sep. 30, 2019	Dec. 31, 2021	Dec. 31, 2020	Nov. 30, 2016
Other Liabilities [Line Items]
Other long-term debt				$ 5.0
Prepayment agreement
Other Liabilities [Line Items]
Other long-term debt	$ 5.0	$ 2.5	$ 2.5
Percentage of prepayment applied against future purchases	100.00%
Period of customer capacity reservation	10 years
Prepayment agreement \| Installment 1
Other Liabilities [Line Items]
Debt instrument, periodic payment	$ 2.5
Prepayment agreement \| Installment 2
Other Liabilities [Line Items]
Debt instrument, periodic payment	$ 2.5
Period of payment of prepayment agreement	30 days

Earnout Liability - Narrative (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period	10 days
Earnout shares of common stock outstanding (in shares) \| shares	25,000,000
Sponsor vesting shares of common stock outstanding (in shares) \| shares	4,500,000
Change in fair value of earnout liability \| $	$ 75,488	$ 0
Earnout liability
Business Acquisition, Contingent Consideration [Line Items]
Earn-out liability \| $	127,800	$ 0
Change in fair value of earnout liability \| $	$ 75,500
Earnout liability \| Dividend yield
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0
Earnout liability \| Expected volatility
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0.82
Earnout liability \| Risk-free interest rate
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0.0118
Earnout liability \| Share trigger price 1
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period	10 days
Share price (in dollars per share) \| $ / shares	$ 15.00
Period from businees combination closing date stock price trigger	3 years
Earnout liability \| Share trigger price 2
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period	10 days
Share price (in dollars per share) \| $ / shares	$ 20.00
Period from businees combination closing date stock price trigger	4 years
Earnout liability \| Share trigger price 3
Business Acquisition, Contingent Consideration [Line Items]
Post triggering event period	10 days
Share price (in dollars per share) \| $ / shares	$ 25.00
Period from businees combination closing date stock price trigger	5 years

Canadian Government Research and Development Program Liability - Narrative (Detail) $ in Millions, $ in Millions	1 Months Ended
	Apr. 30, 2019 CAD ($)	Dec. 31, 2021 USD ($)	Apr. 30, 2021	Dec. 31, 2020 USD ($)
Research and Development [Abstract]
Lesser eligible costs percentage	18.48%
Lesser eligible costs	$ 23.0
Funding repayment period	15 years
Maximum repayment ratio compared to actual funding received	1.25
Funding reduction percentage			50.00%
Minimum costs of commercial plants	$ 500.0
Commercial plants constructed and operational period	30 months
Funding liability		$ 6.8		$ 6.2

Assumed Common Stock Warrants - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Number of warrants or rights outstanding (in shares)	35,476,667
Assumed common stock warrants liability	$ 52,860	$ 0
Change in fair value of gain, assumed warrants	$ 30,500
Share trigger price 1
Class of Warrant or Right [Line Items]
Class of warrants redemption price per unit (in dollars per share)	$ 0.01
Class of warrants redemption notice period	30 days
Warrant instrument redemption threshold consecutive trading days	20 days
Trading period	30 days
Public Warrants
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)	24,150,000
Number of common stock shares converted (in shares)	1
Share price (in dollars per share)	$ 11.50
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)	11,326,667
Number of common stock shares converted (in shares)	1
Share price (in dollars per share)	$ 11.50
Private Warrant
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 12.00
Warrant instrument redemption threshold consecutive trading days	20 days
Trading period	30 days
Minimum lock In period required for warrant exercise from the date of business combination	365 days
Number of days for a particular event to get over for determining trading period	150 days
Common Class A \| Minimum
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	$ 10.00
Common Class A \| Maximum
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	18.00
Common Class A \| Share trigger price 1
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	$ 18.00

Stockholders' Equity - Narrative (Detail) - USD ($)		3 Months Ended	12 Months Ended
Stockholders' Equity - Narrative (Detail) - USD ($)	Feb. 16, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock, shares authorized (in shares)			1,000,000,000	1,000,000,000
Common stock, par value (in dollars per share)			$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)			10,000,000	10,000,000
Common stock, voting rights			one
Common stock, shares outstanding (in shares)			141,301,569	70,266,925
Sponsor vesting shares outstanding (in shares)			4,500,000
Common stock, shares reserved (in shares)			18,467,109
Stock option plan, exercisable period			4 years
Stock options available for grant (in shares)			7,667,247	10,244,399
Stock options, exercisable (in shares)			4,130,184	2,150,941
Stock option, aggregate intrinsic value			$ 49,260,254
Nonvested award, cost not yet recognized			6,600,000
Stock-based compensation			5,767,000	$ 1,630,000
Stock compensation not yet recognized			$ 7,300,000
Stock compensation not yet recognized, vesting period			4 years
Common Stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares)			1,010,000,000
Common stock, par value (in dollars per share)			$ 0.0001
Warrants issued (in shares)			1,000,000,000
Common stock, shares outstanding (in shares)			141,301,569	62,545,275
General and administrative expense
Class of Stock [Line Items]
Stock-based compensation			$ 5,800,000	$ 1,600,000
Research and development expense
Class of Stock [Line Items]
Stock-based compensation			1,300,000	$ 100,000
Performance and market based awards
Class of Stock [Line Items]
Stock options issued during the period (in shares)				2,920,732
Stock options, vested (in shares)	529,119
Stock-based compensation			$ 2,900,000
Performance and market based awards \| First vesting
Class of Stock [Line Items]
Stock option plan, vesting percentage		2.0833%
Stock options, outstanding (in shares)		529,119
Performance and market based awards \| Second vesting
Class of Stock [Line Items]
Stock options, outstanding (in shares)			2,391,613
Restricted stock units (RSUs)
Class of Stock [Line Items]
Option vesting period			3 years
Service period			3 years
Stock compensation not yet recognized			$ 5,400,000
Stock compensation not yet recognized, vesting period			2 years 10 months 24 days
Restricted stock units (RSUs) \| Tranche one
Class of Stock [Line Items]
Stock option plan, vesting percentage			33.30%
Restricted stock units (RSUs) \| Tranche two
Class of Stock [Line Items]
Stock option plan, vesting percentage			33.30%
Restricted stock units (RSUs) \| Tranche three
Class of Stock [Line Items]
Stock option plan, vesting percentage			33.30%
Options to purchase common stock
Class of Stock [Line Items]
Stock options issued during the period (in shares)			0	6,296,302
Stock compensation not yet recognized, vesting period			2 years 7 months 6 days
Share-based payment arrangement, nonemployee
Class of Stock [Line Items]
Stock option plan, exercisable period			10 years
One year from the vesting commencement date
Class of Stock [Line Items]
Stock option plan, vesting percentage			25.00%
Employee Stock Purchase Plan (ESPP) \| Employee stock
Class of Stock [Line Items]
Number of shares authorized (in shares)			1,846,710
Percentage of fully diluted shares of common stock			1.00%
Percentage of ESPP share reserve			200.00%
Purchase price of common stock, percent			85.00%
Stock Incentive Plan \| More than one year from vesting commencement date
Class of Stock [Line Items]
Stock option plan, vesting percentage			2.778%

Stockholders' Equity - Summary of Stock Option Activity (Detail) - Options to purchase common stock - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Outstanding Options
Beginning balance (in shares)	8,222,710	2,205,015
Granted (in shares)	0	6,296,302
Exercised (in shares)	(171,118)	(2,912)
Forfeited / canceled (in shares)	(158,735)	(275,695)
Ending balance (in shares)	7,892,857	8,222,710	2,205,015
Vested and expected to vest (in shares)	7,872,978
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.19	$ 0.36
Granted (in dollars per share)		0.14
Exercised (in dollars per share)	0.42	0.37
Forfeited / canceled (in dollars per share)	0.14	0.43
Ending balance (in dollars per share)	$ 0.19	$ 0.19	$ 0.36
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years)	7 years 3 months 21 days	8 years 3 months 18 days	3 years 10 months 20 days

Stockholders' Equity - Summary of RSU and Performance Award Activity (Detail)	12 Months Ended
	Dec. 31, 2021 $ / shares shares
RSUs and performance shares
Outstanding
Beginning balance (in shares)	0
Ending balance (in shares)	2,907,005
Expected to vest (in shares)	769,505
Weighted-average grant date fair value
Ending balance (in dollars per share) \| $ / shares	$ 7.35
Restricted stock units (RSUs)
Outstanding
Granted (in shares)	769,505
Weighted-average grant date fair value
Granted (in dollars per share) \| $ / shares	$ 7.34
Performance shares
Outstanding
Granted (in shares)	2,137,500
Weighted-average grant date fair value
Granted (in dollars per share) \| $ / shares	$ 7.35

Income Taxes - Income before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
United States	$ 43,645	$ (29,162)
International	(1,554)	(1,141)
Income before income taxes	$ 42,091	$ (30,303)

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

Income Taxes - Federal and State Income Tax Provision (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current
Federal	$ 0	$ 0
State	3	2
International	0	0
Total current tax expense	3	2
Deferred
Federal	0	0
State	0	0
International	0	0
Total deferred tax expense	0	0
Total tax expense	$ 3	$ 2

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets
Net operating loss carryforwards	$ 24,899	$ 18,400
Available for Sale Securities	390	0
Lease liability	341	0
Other	230	149
Fixed assets and intangibles	89	114
Total deferred tax assets	25,949	18,663
Deferred tax liabilities
ROU asset	(344)	0
Total deferred tax liabilities	(344)	0
Valuation allowance	(25,605)	(18,663)
Net deferred taxes	$ 0	$ 0

Income Taxes - Narrative (Detail) - USD ($)	12 Months Ended
Income Taxes - Narrative (Detail) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance	$ 6,900,000	$ 1,900,000
Federal operating loss carryforward	97,800,000
Operating loss carryforward, state	36,800,000
Operating loss carryforward, foreign	6,700,000
Unrecognized tax benefits	0	$ 0
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforward subject to expiration	44,900,000
Operating loss carryforward not subject to expiration	52,900,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, research	$ 0

Income Taxes - Effective Tax Rate (Detail)	12 Months Ended
Income Taxes - Effective Tax Rate (Detail)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory rate	21.00%	21.00%
State tax	(1.30%)	(0.10%)
Warrants, BCF, and other equity items	(33.30%)	(13.10%)
Valuation allowance	15.60%	(6.40%)
Other	(0.20%)	(0.10%)
Foreign rate differential	(0.20%)	0.20%
Stock-based compensation	(1.60%)	(1.50%)
Effective income tax rate	0.00%	0.00%

Leases - Narrative (Detail) $ in Thousands	12 Months Ended
Leases - Narrative (Detail) $ in Thousands	Dec. 31, 2021 USD ($) lease	Jan. 01, 2021 USD ($)	Dec. 31, 2020 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease right-of-use asset	$ 1,782	$ 1,800	$ 0
Number of amended leases (in leases) \| lease	2
Sacramento, California lease agreement
Lessee, Lease, Description [Line Items]
Operating lease term	7 years
Operating lease right-of-use asset	$ 900
Sarnia, Ontario lease agreement
Lessee, Lease, Description [Line Items]
Operating lease term	18 months
Operating lease right-of-use asset	$ 100
Minimum
Lessee, Lease, Description [Line Items]
Remaining operating lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining operating lease term	9 years

Leases - Components of Lease Cost (Detail) $ in Thousands	12 Months Ended
Leases - Components of Lease Cost (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Leases [Abstract]
Operating lease cost	$ 324
Variable lease cost	68
Total lease cost	$ 392

Leases - Other Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2021
Right of Use Assets:
Operating lease ROU asset (included within Lease right-of-use asset)	$ 1,782	$ 0	$ 1,800
Weighted average remaining lease term (in years):
Operating leases	7 years 5 months 8 days
Weighted average discount rate:
Operating leases	2.80%
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 271
Right-of-Use Asset Obtained In Exchange for Lease Liability:
ROU assets obtained in exchange for operating lease liabilities	$ 2,062	$ 0

Leases - Operating Lease Maturity (Detail) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 327
2023	300
2024	269
2025	257
2026	264
Thereafter	528
Total lease payments	1,945
Less: imputed interest	(179)
Less: lease liabilities, current	(280)	$ 0
Lease liabilities, non-current	$ 1,486	$ 0

Commitments and Contingencies - Narrative (Detail) MMBTU in Thousands						1 Months Ended			12 Months Ended
	May 31, 2019	Jul. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Nov. 30, 2016 USD ($)	Aug. 31, 2015 USD ($)	May 31, 2019 MMBTU	May 31, 2018 USD ($)	Jun. 30, 2011 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Other Commitments [Line Items]
Service agreement, periods							5 years		3 years
Operating and maintenance agreements, automatic extension periods							1 year
Property, plant, and equipment, net									$ 0	$ 0
Service agreement, percentage of steam receivable thereafter	50.00%
License agreement amount		$ 100,000	$ 500,000	$ 35,000
Royalty payment per year		5,000		25,000				$ 5,000
Royalty payment, cumulative amount			500,000		$ 10,000,000
Upfront license fee royalty and a variable royalty, aggregate cap per facility			$ 10,000,000
License payment, royalty payment									$ 0	$ 0
Percentage of net sales								0.40%
Minimum
Other Commitments [Line Items]
Operating and maintenance agreements, fixed payments per year							$ 400,000
Maximum
Other Commitments [Line Items]
Service agreement, percentage of steam receivable during first year	25.00%
Service agreement, MMBtus per year generated \| MMBTU \| MMBTU						140
Royalty payment per year		$ 25,000
Royalty payment, cumulative amount				$ 1,000,000	$ 2,000,000

Basic and Diluted Net Income (Loss) Per Share - Summary of Basic And Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net income (loss) attributable to common stockholders—Basic	$ 42,090	$ (30,302)
Net income (loss) attributable to common stockholders—Diluted	$ 42,090	$ (30,302)
Denominator:
Weighted-average common shares outstanding—Basic (in shares)	101,221,781	62,544,933
Weighted-average common shares outstanding—Diluted (in shares)	106,237,754	62,544,933
Net income (loss per share)—Basic (in dollars per share)	$ 0.42	$ (0.48)
Net income (loss per share)—Diluted (in dollars per share)	$ 0.40	$ (0.48)
Options to purchase common stock
Denominator:
Dilutive share based payment arrangements (in shares)	4,954,919	0
RSU awards
Denominator:
Dilutive share based payment arrangements (in shares)	61,054	0

Basic and Diluted Net Income (Loss) Per Share - Summary of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	8,222,710
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	35,476,667	0
Warrants to purchase redeemable convertible preferred stock, as-converted
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	2,678,320	5,554,470

Basic and Diluted Net Income (Loss) Per Share - Narrative (Detail) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Weighted-average sponsor vesting shares subject to return (in shares)	2,342,466	0
Shares of common stock (in shares)	1,481,531
Performance shares outstanding (in shares)	2,137,500
Earnout shares of common stock outstanding (in shares)	25,000,000
Sponsor vesting shares of common stock outstanding (in shares)	4,500,000